0001607062-24-000033.txt : 20240119 0001607062-24-000033.hdr.sgml : 20240119 20240119132902 ACCESSION NUMBER: 0001607062-24-000033 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Regen BioPharma Inc CENTRAL INDEX KEY: 0001589150 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 455192997 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-191725 FILM NUMBER: 24544906 BUSINESS ADDRESS: STREET 1: 4700 SPRING ST #304 CITY: LA MESA STATE: CA ZIP: 91942 BUSINESS PHONE: 619-722-5505 MAIL ADDRESS: STREET 1: 4700 SPRING ST #304 CITY: LA MESA STATE: CA ZIP: 91942 10-Q 1 rgbp123123form10q.htm 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

Commission File No. 333-191725

REGEN BIOPHARMA INC

(Exact name of small business issuer as specified in its charter)

Nevada	45-5192997
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

619 722-5505

(Issuer’s telephone number)

None

(Former name, address and fiscal year, if changed since last report)

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐ No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐ Large accelerated filer	☐ Accelerated filer
☒ Non-accelerated filer	☒ Smaller reporting company
	☐ Emerging Growth Company

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of December 31, 2023 Regen Biopharma, Inc. had 3,750,565 common shares outstanding.

As of December 31, 2023 Regen Biopharma, Inc. had 409,551 shares of Series A Preferred Stock outstanding.

As of December 31, 2023 Regen Biopharma, Inc. had 34 shares of Series AA Preferred Stock outstanding.

As of December 31, 2023 Regen Biopharma, Inc. had 29,338 shares of Series M Preferred Stock outstanding.

As of December 31, 2023 Regen Biopharma, Inc. had 15,007 shares of Series NC Preferred Stock outstanding

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements


REGEN BIOPHARMA , INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

	As of
	December 31, 2023			September 30, 2023
		(unaudited)
ASSETS
CURRENT ASSETS
Cash	$	124,497		$	121,037
Accounts Receivable, Related Party		12,298			0
Note Receivable, Related Party					0
Prepaid Expenses					0
Prepaid Rent		5,000			10,000
Total Current Assets		141,795			131,037

OTHER ASSETS
Investment Securities, Related Party		17,733			222,580
Total Other Assets		17,733			222,580
TOTAL ASSETS	$	159,528		$	353,617

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		44,183			29,674
Notes Payable		49,210			95,710
Accrued payroll taxes		4,241			4,241
Accrued Interest		360,353			342,588
Accrued Payroll		1,256,630			1,256,630
Other Accrued Expenses		41,423			41,423
Bank Overdraft		1,000			1,000
Due to Investor		20,000			20,000
Unearned Income		1,560,091			1,591,731
Unearned Income ( Related Party)		0			15,126
Derivative Liability		1,400,000			1,400,000
Convertible Notes Payable Less unamortized discount		499,880			499,880
Convertible Notes Payable, Related Parties Less unamortized discount		10,000			10,000
Total Current Liabilities		5,247,010			5,308,003
Long Term Liabilities:
Convertible Notes Payable, Related Parties Less unamortized discount		—
Notes Payable		153,981			149,614
Total Long Term Liabilities		153,981			149,614
Total Liabilities		5,400,991			5,457,617

STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value); 5,800,000 shares authorized and 3,750,565 issued and outstanding as of December 31, 2023 and 3,506,366 shares issued and outstanding as of September 30,2023.		376			352
Preferred Stock, 0.0001 par value, 800,000,000 authorized as of December 31, 2023 and September 30, 2023 respectively		—
Series A Preferred; 739,000,000 authorized as of September 30, 2023 and December 31,2023 409,551 outstanding as of December 31, 2023 and September 30, 2023		40			40
Series AA Preferred; $0.0001 par value 600,000 authorized and 34 and 34 outstanding as of December 31, 2023 and September 30,2023 respectively		0			0
Series M Preferred; $0.0001 par value 60,000,000 authorized and 29,338 outstanding as of September 30, 2023 and 60,000,000 authorized and 29,338 outstanding as of December 31, 2023		3			3
Series NC Preferred; $0.0001 par value 20,000 authorized and 15,007 outstanding as of September 30, 2023 and December 31, 2023		2			2
Additional Paid in capital		14,120,412			13,908,141
Contributed Capital		736,326			736,326
Retained Earnings (Deficit)		(20,098,623	)		(19,748,863	)
Total Stockholders' Equity (Deficit)		(5,241,463	)		(5,104,000	)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$	159,528		$	353,617

The Accompanying Notes are an Integral Part of These Financial Statements
All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023


REGEN BIOPHARMA , INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

	Quarter Ended December 31,2023			Quarter Ended December 31,2022
REVENUES
Revenues	$	31,640		$	31,640
Revenues, Related Party		27,425			27,425
TOTAL REVENUES		59,065			59,065

COST AND EXPENSES
Research and Development		47,528			95,513
General and Administrative		12,419			8,738
Consulting and Professional Fees		106,900			403,680
Rent		15,000			15,000
Total Costs and Expenses		181,846			522,931
OPERATING INCOME (LOSS)	$	(122,782	)	$	(463,867	)

OTHER INCOME & (EXPENSES)
Interest Expense		(17,764	)		(17,359	)
Interest Expense attributable to Amortrization of Discount		(4,367	)		0
Unrealized Gain ( Loss) on sale of Investment Securites		(204,847	)		0
Derivative Income (Expense)		0			2,115,806
Gain (Loss) on Extinguishment Convertible Debt		0			1,150
TOTAL OTHER INCOME (EXPENSE)		(226,978	)		2,099,597

NET INCOME (LOSS)		(349,760	)		1,635,730
NET INCOME (LOSS) attributable to common shareholders		(349,760	)		1,448,439

BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE	$	(0.10	)	$	0.4500
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING		3596027			3360540

The Accompanying Notes are an Integral Part of These Financial Statements
All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIT)

(unaudited)

Quarter Ended December 31, 2023


			Series A Preferred				Series AA Preferred				Series NC				Common				Series M Preferred
			Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital		Retained Earnings			Contributed Capital		Total
Balance September 30, 2023	Balance September 30, 2023			409,551	$	40		34	$	0		15,007	$	2		3,506,366	$	352		29,338		3	$	13,908,141	$	(19,748,863	)	$	736,326	$(5,104,000)
Common Shares issued for Cash	10/13/2023	Common Shares issued for Cash														16,710		2						22,724						22,726
Common Shares issued for Cash	10/27/2023	Common Shares issued for Cash														35,785		4						46,088						46,091
Common Shares issued for Cash	11/10/2023	Common Shares issued for Cash														31,732		3						38,202						38,205
Common Shares issued for Cash	11/27/2023	Common Shares issued for Cash														33,989		3						32,626						32,629
Common Shares issued for Cash	12/11/2023	Common Shares issued for Cash														43,297		4						38,097						38,101
Common Shares issued for Cash	12/20/2023	Common Shares issued for Cash														82,686		8						34,535						34,543
	Net Income (Loss) Quarter Ended December 31, 2023					—				—				—				—				—		—		(349,760	)		—	(349,760)
Balance December 31, 2023	Balance December 31, 2023			409,551	$	40		34	$	0		15,007				3,750,565		376		29,338		3		14,120,412		(20,098,623	)		736,326	(5,241,463)

	The Accompanying Notes are an Integral Part of These Financial Statements
	All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY ( DEFICIT)

(unaudited)

Quarter Ended December 31, 2022


			Series A Preferred				Series AA Preferred				Series NC				Common				Series M Preferred
			Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital		Retained Earnings			Contributed Capital		Total
Balance September 30, 2022	Balance September 30, 2022		—		—		—		—		—		—		—		—		—		—		—		—			—		—
	10/25/2022	Preferred Shares Issued for Nonemployee Services		6,667	$	1																		299,999						$300,000
Preferred Shares Issued for Debt	11/11/2022	Preferred Shares Issued for Debt		70,114	$	7																		761,493						$761,500
Preferred Shares Issued for Interest	11/11/2022	Preferred Shares Issued for Interest		35,012	$	4																		380,258						$380,262
Common Shares Issued For Interest	11/11/2022	Common Shares Issued For Interest														11,279	$	1						25,368						25,369
	12/5/2022	Preferred Shares Issued for Nonemployee Services		1,112	$	0																		48,372						$48,372
		Net Income for the Quarter ended December 31, 2022				—				—				—				—				—		—		1,635,730			—	1,635,730
Balance December 31,2022	Balance December 31,2022			405,958	$	40		34	$	0		7	$	—		3,366,165	$	337		29,338		3	$	13,648,107	$	(19,269,640	)	$	736,326	$(4,884,827)

	The Accompanying Notes are an Integral Part of These Financial Statements
	All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023


REGEN BIOPHARMA , INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
	Three Months Ended			Three Months Ended
	December 31, 2023			December 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$	(349,760	)	$	1,635,730
Adjustments to reconcile net Income to net cash
Preferred Stock issued as compensation					348,372
Increase (Decrease) in Interest expense attributable to amortization of Discount		4,367
Increase (Decrease) in Accounts Payable		14,509			2,240
(Increase) Decrease in Accounts Receivable		(12,298	)		122,575
Increase (Decrease) in accrued Expenses		17,765			17,359
(Increase) Decrease in Prepaid Expenses		5,000			11,856
Increase(Decrease) in Contributed Capital		—
Increase ( Decrease) in Derivative Expense					(2,115,806	)
Increase ( Decrease) in Unearned Income		(46,767	)		(31,640	)
(Gain) Loss on forgiveness of Debt					(1,150	)
Unrealized Loss(Gain) on Investment Securities		204,847
Net Cash Provided by (Used in) Operating Activities	$	(162,336	)	$	(10,463	)


CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in Convertible Notes Payable		—
Increase (Decrease) in Notes Payable		(46,500	)		0
Increase ( Decrease) in Common Stock issued for cash		212,297			0
Net Cash Provided by (Used in) Financing Activities	$	165,797		$	—


Net Increase (Decrease) in Cash	$	3,460		$	(10,463	)
Cash at Beginning of Period	$	121,037		$	51,204
Cash at End of Period	$	124,497		$	40,741

Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt	$	—		$	—
Preferred Shares Issued for Debt	$	—		$	761,500
Cash Paid for Interest	$	—		$	—
Common shares Issued for Interest	$	—		$	25,269
Preferred Shares issued for Interest	$	—		$	380,262

The Accompanying Notes are an Integral Part of These Financial Statements
All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

REGEN BIOPHARMA, INC.

Notes to Condensed Consolidated Financial Statements

As of December 31, 2023

These Notes have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada

The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.

The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease.

The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company.

A. BASIS OF ACCOUNTING

The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated.

The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model.

The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of December 31, 2023 utilized the following inputs:


Schedule of Derivative liability
Risk Free Interest Rate	5.29	%
Expected Term	(2.78) – (3.41) Yrs
Expected Volatility	932.98	%
Expected Dividends

H. INCOME TAXES

The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date.

The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2023 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future.

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE

The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception.

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31, 2022 and December 31, 2023.

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

L. REVENUE RECOGNITION

Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products.

The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard.

As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification.

The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements.

In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure.

On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements.

On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following:

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position.

On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position.

In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019.

In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity (“ASU 2020-06"), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity, and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company has adopted ASU 2020-06 as of the Fiscal Year ending September 30, 2022.

A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $20,098,623 during the period from April 24, 2012 (inception) through December 31, 2023. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

On September 12, 2023 the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Coventry Enterprises LLC ( “Coventry”) providing for an equity financing facility (the “Equity Line”). The Equity Line Agreement provides that upon the terms and subject to the conditions in the Equity Line Agreement, Coventry is committed to purchase up to Ten Million Dollars ($10,000,000) of shares of common stock, $0.0001 par value per share (the “Common Stock”), over the 36-month term of the Equity Line Agreement (the “Total Commitment”).

Under the terms of the Equity Line Agreement, Coventry will not be obligated to purchase shares of Common Stock unless and until certain conditions are met, including but not limited to a Registration Statement on Form S-1 (the “Registration Statement”) becoming effective which registers Coventry’s resale of any Common Stock purchased by Coventry under the Equity Line.

From time to time over the 36-month term of the Commitment Period ( as such term is defined in the Equity Line Agreement) the Company, in its sole discretion, may provide Coventry with a draw down notice (each, a “Draw Down Notice”), to purchase a specified number of shares of Common Stock (each, a “Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Draw Down Notice (each, a “Draw Down Amount”) is to be determined by multiplying the Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of Common Stock equals 80% of the lowest trading price of the Common Stock during the ten business days prior to the Draw Down Notice date (the “Pricing Period”).

The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 200% of the Average Daily Traded Value ( as such term is defined in the Equity Line Agreement) during the ten business days immediately preceding the Drawdown Notice Date or (ii) $250,000. The Company is prohibited from delivering a Draw Down Notice if the sale of shares of Common Stock pursuant to the Draw Down Notice would cause the Company to issue and sell to Coventry or Coventry to acquire or purchase an aggregate number of shares of Common Stock that would result in Coventry beneficially owning more than 4.99% of the issued and outstanding shares of Common Stock of the Company.

The Company issued Coventry 125,000 shares of its Common Stock in connection with the Equity Line Agreement.

Coventry has agreed that:

(a)

for so long as the market price of the Company’s common stock is above $1.25 per share and

(b)

the Company is in full compliance with all agreements entered into with Coventry and

(c)

and the Company has not issued any common shares at a per share price below $1.50, Coventry will agree to a leak out provision and will not sell more than 10,000 shares of the Commitment shares without permission from the Issuer.

In connection with the Equity Line Agreement the Company also entered into a Registration Rights Agreement, dated September 12, 2023 with Coventry (the “Registration Rights Agreement”), pursuant to which the Company agreed to register for resale under the Securities Act of 1933 shares issuable in accordance with the Equity Line Agreement as well as the aforementioned 125,000 common shares issued in connection with the Equity Line Agreement in a Registration Statement to be filed with the Securities and Exchange Commission. Up to 1,126,954 Shares of Common Stock were registered for resale under the Securities Act of 1933 pursuant to the Registration Rights Agreement.

During the quarter ended December 31, 2023 the Company issued 244,199 common shares pursuant to the Equity Line Agreement for aggregate cash consideration of $212,296.

NOTE 4. NOTES PAYABLE

(a) RELATED PARTY

Schedule of notes payable related party
	As of December 31, 2023
David Koos	$	710
Total:	$	710

$710 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

(b) NON RELATED PARTY As of December 31, 2023


Bostonia Partners, Inc.	$	48,500
Coventry Enterprises LLC	$	175,000
Total:	$	223,500

$48,500 lent to the Company by Bostonia Partners, Inc is due and payable on March 10, 2024 and bears simple interest at a rate of 10% per annum.

Effective September 12, 2023 Coventry Enterprises purchased a 10% unsecured promissory Note (the “Note”) from the Company in the principal amount of $175,000 of which $26,250 was retained by Coventry through an Original Issue Discount.

The Note carries “Guaranteed Interest” on the principal amount at the rate of 10% per annum for the eighteen-month term of the Note for an aggregate Guaranteed Interest $26,250. The Principal Amount and the Guaranteed Interest shall be due and payable in seven equal monthly payments of $28,750 commencing on August 12, 2024 and continuing on the 12th day of each month thereafter until paid in full not later than March 12, 2025 (the “Maturity Date”).

Upon an Event of Default (as such term is defined in the Note) the Note shall become convertible, in whole or in part, into shares of Common Stock at the option of the Holder at price per share equivalent to 90% of the lowest per-share trading price for the 20 Trading Days preceding a Conversion Date.

Upon the event that while this Note has been outstanding for four months, the Company consummates another financing transaction or if the Company has an effective Regulation A Offering Statement then the Investor may choose to convert any amount up to the entire balance of the note including guaranteed interest into shares at the same offering price as the aforementioned financing transaction or the Regulation A Offering..

NOTE 5. CONVERTIBLE NOTES PAYABLE

On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum. The maturity of the Note is three years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions:

(a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1") a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater).

(b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2") a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater).

(c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3") a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater).

(d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities.

The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

Upon closing of a Transaction Event the Lender shall receive 0.10% (one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property

As of December 31, 2023 $100,000 of the principal amount of the Note remains outstanding.

On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum. The maturity of the Note is three years from the issue date.

Upon closing of a Transaction Event the Lender shall receive 0.10% (one tenth of one percent) of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

As of December 31, 2023 $50,000 of the principal amount of the Note remains outstanding.

On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is two years from the issue date.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $18.75 per share.

The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest.

As of December 31, 2023 $50,000 of the principal amount of the Note remains outstanding.

On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May 5, 2020. The Note is convertible into the Common Shares of Regen at a price per share (“Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $375 per common share as of the date which is the earlier of:

(i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction.

ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”).

(iii) That date which is twenty four (24) months subsequent to the date of execution of this Note.

In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $75 per share.

The warrants shall be exercisable:

In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”)

In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note

As of December 31, 2023 $200,000 of the principal amount of the Note remains outstanding.

The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $800,000 was recognized by the Company as of December 31, 2023.

On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 20, 2020. The Note may be converted into the Common Shares of Regen at a price per share (“Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $37.50 per common share as of the date which is the earlier of:

(i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction.

(ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”).

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31, 2023 $100,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $400,000 was recognized by the Company as of December 31, 2023.

On October 3, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 3, 2020. The Note may be converted into the Common Shares of Regen at a price per share (“Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $37.5 per common share as of the date which is the earlier of:

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31, 2023, $50,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $200,000 was recognized by the Company as of December 31, 2023.

On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date.

Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen.

As of December 31, 2023, 10,000 of the principal amount of the Note remains outstanding.

Zander and Regen are under common control. Zander Therapeutics, Inc. is the sole licensee of Regen’s NR2F6 intellectual property for veterinary applications.

NOTE 6. RELATED PARTY TRANSACTIONS

On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. (“Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company.

Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement.

The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander.

Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter.

Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees (excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement).

Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000).

The Agreement may be terminated by The Company:

If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product.

The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP.

The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated.

The Agreement may be terminated by either party in the event of a material breach by the other party.

On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto.

On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby:

1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement.

2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement.

3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.

No actions were taken by any of the parties to enforce the terms of the Agreement.

On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:

a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return

b) As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 (“License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto.

Zander and Regen are under common control.

As of December 31, 2023, $10,000 of the principal amount of the Note remains outstanding.

On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of :

a) Reviewing existing publications on research being conducted on Checkpoint NR2F6.

b) Identifying the most promising applications for the Company’s technology

c) Drafting a “white paper” on results for 1(b)

d) Making introductions to known experts in appropriate fields identified in 1(b).

Dr. Brian Koos is to be paid compensated $117,000 as total consideration for performing the abovementioned tasks. During the quarter ended December 31, 2021 Dr. Brian Koos was paid the amount of $80,275 and during the quarter ended June 30, 2022 Dr. Brian Koos was paid $36,975. Dr. Brian Koos is the brother of David Koos the Chairman and Chief Executive Officer of the Company.

As of December 31, 2023 the Company is indebted to David R. Koos the Company’s sole officer and director in the amount of $710. $710 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum.

On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022.

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

NOTE 7. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company contains the following classes of capital stock as of December 31, 2023:

Common stock, $ 0.0001 par value; 5,800,000 shares authorized: 3,750,565 shares issued and outstanding.

With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation.

Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 34 shares issued and outstanding as of December 31, 2023, 739,000,000 is designated Series A Preferred Stock of which 409,551 shares are outstanding as of December 31, 2023, 60,000,000 is designated Series M Preferred Stock of which 29,338 shares are outstanding as of December 31, 2023, and 20,000 is designated Series NC stock of which 15,007 shares are outstanding as of December 31, 2023..

The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired.

Series AA Preferred Stock

On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”).

The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times seven (7). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Series A Preferred Stock

On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”).

The Board of Directors of the Company have authorized 739,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock.

Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them.

If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board.

On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series M Preferred Stock” (hereinafter referred to as “Series M Preferred Stock”).

The Board of Directors of Regen have authorized 60,000,000 shares of the Series M Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series M Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series M Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series M Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore

On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

On March 26, 2021 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock (hereinafter referred to as “Series NC Preferred Stock”).

The Board of Directors of Regen have authorized 20,000 shares of the Series NC Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series NC Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series NC Preferred Stock owned by such holder times 334. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series NC Preferred Stock shall vote as a single class on all matters submitted to the stockholders.

The holders of Series NC Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore

On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

NOTE 8. INVESTMENT SECURITIES, RELATED PARTY

On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.

On November 29, 2018 the Company accepted 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $13,124.

On December31, 2023 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and 725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs:


Fair Value of Intellectual Property	$	300,000
Prepaid Expenses		65,661
Due from Employee		0
Note Receivable		40000
Accrued Interest Receivable		35,000
Investment Securities		258,255
Convertible Note Receivable		10,000
Accounts Payable		30,563
Notes Payable		400,000
Accrued Expenses Related Parties		162,011
Notes Payable Related Party		0
Accrued Expenses		647,072
Enterprise Value		1,948,562
Less: Total Debt		(1,239,646	)
Portion of Enterprise Value Attributable to Shareholders	$	708,916
Fair Value per Shares	$	0.02

The abovementioned constitute the Company’s sole related party investment securities as of December 31, 2023.

As of December 31, 2023:

	Schedule of comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2023
$	5,741	$	6,496	$	755	$	(81,112)

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss		Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2023
$	13,124	$	11,238	$	(1,866)	$	(123,733)

NOTE 9. STOCK TRANSACTIONS

On October 13 2023 the Company issued 16,710 common shares for cash consideration of $22,726.

On October 27 2023 the Company issued 35,785 common shares for cash consideration of $46,091.

On November 10, 2023 the Company issued 31,732 common shares for cash consideration of $38,205.

On November 27, 2023 the Company issued 33,989 common shares for cash consideration of $32,629.

On December 11 2023 the Company issued 43,297 common shares for cash consideration of $38,101.

On December 20, 2023 the Company issued 82,686 common shares for cash consideration of $34,543.

NOTE 10. SUBSEQUENT EVENTS

On January 3, 2024 the Company issued 94,883 common shares for cash consideration of $39,638.

On January 10, 2024 the Company issued 82,643 common shares for cash consideration of $39,638.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN FORWARD-LOOKING INFORMATION

Information provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company’s expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company’s operations, economic performance, financial conditions, margins and growth in sales of the Company’s products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission. All references to” We”, “Us”, “Company” or the “Company” refer to Regen BioPharma, Inc.

As of December 31, 2023 we had Accounts Receivable, Related Party of $12,298 and as of September 30, 2023 we had Accounts Receivable, Related Party of $0. Accounts Receivable, Related Party as of December 31, 2023 consists of fees accrued but not yet paid pursuant to a license granted to Zander Therapeutics, Inc. by Regen Biopharma, Inc.

As of December 31, 2023 we had Prepaid Rent of $5,000 and as of December 31, 2022 we had Prepaid Rent of $10,000. The decrease in Prepaid Rent of 50% is attributable to the cash payment by the Company of $10,000 out of $15,000 rent expenses incurred during the quarter ended December 31, 2023.

As of December 31, 2023 we had Investment Securities (Related Party) of $17,733 and as of September 30, 2023 we had Investment Securities (Related Party) of $222,580. During the quarter ended December 31, 2023 the Company revalued its owned shares of Zander Therapeutics, Inc. resulting in the recognition of a decrease in fair value of 92.3% as compared to September 30, 2023.

As of December 31 2023 we had Accounts Payable of $44,183 and as of September 30, 2023 we had Accounts Payable of $29,674. The decrease of 48.9% in Accounts Payable during the quarter ended December 31, 2023 is attributable to:

(a) patent prosecution expenses incurred during the quarter ended December 31, 2023 of $14,839

(b) Transfer Agency fees of $550

offset by satisfaction of $875 in payables recognized during the quarter ended September 30, 2023.

As of December 31, 2023 we had Current Notes Payable of $49,210 and as of September 30, 2023 we had Current Notes Payable of $95,710. The reduction in Current Notes Payable of approximately 48.6% is attributable to repayment of $46,500 of outstanding principal indebtedness during the quarter ended December 31, 2023.

As of December 31, 2023 we had Accrued Interest Payable of $360,353 and as of September 30, 2023 we had Accrued Interest Payable of $342,588.The increase in Accrued Interest Payable of 5.2% is attributable to interest accrued but unpaid during the quarter ended December 31, 2023 on Notes Payable and Convertible Notes Payable.

On December 31, 2023 we had Unearned Income, Related Party of $0 and as of September 30, 2023 we had Unearned Income, Related Party of $15,126. Unearned Income (Related Party) as of September 30, 2023 consisted solely of licensing fees paid to the Company by Zander Therapeutics, Inc. but not yet earned. These fees were earned during the quarter ended December 31, 2023. Zander Therapeutics, Inc. and the Company are under common control.

Revenues from continuing operations were $59,065 for the quarter ended December 31, 2023 and $59,065 for the same period ended 2022. $27,425 of revenue from related parties recognized during the three months ended December 31, 2023 and December 31, 2022 consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. and minimum royalties recognized during the three months ended December 31, 2023 and 2022 respectively pursuant to the same license. $31,640 of revenue recognized during the three months ended December 31, 2023 were recognized pursuant to licenses granted to Oncology Pharma,Inc. and $31,640 of revenue was recognized during the quarter ended December 31 , 2022 pursuant to those same licenses.

The Company recognized an Operating Loss of $122,782 during the quarter ended December 31, 2023 whereas the Company recognized an Operating Loss of $463,867 for the same period ended 2022. The large disparity in Operating Losses is primarily attributable to greater Research and Development and Consulting Expenses recognized during the quarter ended December 31, 2023 as compared to the same quarter ended 2022. The Company recognized Net Income of $1,635,730 during the quarter ended December 31, 2022 whereas the Company recognized a Net Loss of $349,760 during the same period ended 2023. Net Income of $1,635,730 recognized during the quarter ended December 31, 2022 was primarily attributable to Recognition of Derivative Income of $2,115,806 recognized during the quarter ended December 31, 2022.

As of December 31, 2023 we had $124,497 in cash on hand and current liabilities of $5,247,010 such liabilities materially consisting of Accounts Payable, Notes Payable, Convertible Notes Payable, Derivative Liability Recognized, Unearned Income and Accrued Expenses. We feel we will not be able to satisfy our cash requirements over the next twelve months and shall be required to seek additional financing.

During the quarter ended December 31, 2023 the Company sold 244,199 common shares to Coventry pursuant to the terms and conditions of the Equity Line Agreement for total cash consideration of $212,297. During the period beginning January 1, 2024 and ending January 15, 2024 the Company sold the following number of common shares to Coventry pursuant to terms and conditions of the Equity Line Agreement:

On January 3, 2024 the Company issued 94,883 common shares for cash consideration of $39,638.

On January 10, 2024 the Company issued 82,643 common shares for cash consideration of $39,638.

As of December 31, 2023 the Company was not party to any binding agreements which would commit Regen to any material capital expenditures.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, as defined by Rule 229.10(f) (1) of Regulation S-K, we are not required to provide the information required by this Item. We have chosen to disclose, however, that we have not engaged in any transactions, issued or bought any financial instruments or entered into any contracts that are required to be disclosed in response to this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company’s Principal Executive Officer and Principal Financial Officer of the effectiveness of the design and operation of the Company’s disclosure controls and procedures. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company’s disclosure control objectives. The Company’s Principal Executive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures are, in fact, effective at this reasonable assurance level as of the period covered.

Changes in Internal Controls over Financial Reporting

In connection with the evaluation of the Company’s internal controls during the period commencing on October 1, 2023 and ending on December 31, 2023, David Koos, who serves as the Company’s Principal Executive Officer , Principal Financial Officer has determined that there were no changes to the Company’s internal controls over financial reporting that have been materially affected, or is reasonably likely to materially effect, the Company’s internal controls over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings.

None

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of equity securities during the quarter ended December 31, 2023.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Submission Of Matters To A Vote Of Security Holders

None.

Item 5. Other Information

On October 4, 2023 a 10b5-1 trading arrangement ( “10b5-1 Plan”) adopted by Zander Therapeutics, Inc. was terminated pursuant to the terms and conditions of that 10b5-1 Plan. The 10b5-1 Plan was adopted on November 4, 2021. The arrangement was adopted to facilitate the sale by Zander Therapeutics Inc. of 2,667 shares of Series A Preferred stock of the Company owned by Zander Therapeutics, Inc. The terms and conditions of the 10b5-1 Plan allowed for the sale of up to 67 shares per day at a price no lower than $30 below opening bid price. Zander Therapeutics, Inc. is controlled by David Koos who serves as the sole officer and director of the Company.*

* share amounts and price information have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023.

Item 6. Exhibit Index

Exhibit No. Description

31.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
31.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANESE-OXLEY ACT OF 2002
32.1	CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
32.2	CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Regen Biopharma, Inc.

	By:	/s/ David R. Koos
	Name:	David R. Koos
	Title:	Chairman, Chief Executive Officer

	Date:	January 19, 2024

		Regen Biopharma, Inc.

	By:	/s/ David R. Koos
	Name:	David R. Koos
	Title:	Acting Chief Financial Officer, Director

	Date:	January 19, 2024

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Koos certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2023 of Regen Biopharma, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant’s, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles:

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: January 19, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Exeuctive Officer

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David R. Koos certify that:

1. I have reviewed this quarterly report on Form 10-Q for the period ended December 31, 2023 of Regen Biopharma, Inc.;

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: January 19, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Financial Officer

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Regen Biopharma, Inc. on Form 10-Q for the period ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David R. Koos, Chief Financial Officer certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: January 19, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Executive Officer

EX-32.2 5 ex32_2.htm EXHIBIT 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: January 19, 2024	By:	/s/ David R. Koos
		David R. Koos
		Chief Financial Officer

EX-101.SCH 6 rgbp-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIT) (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - CONVERTIBLE NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - STOCK TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - NOTES PAYABLE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - CONVERTIBLE NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - STOCK TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rgbp-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 rgbp-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 9 rgbp-20231231_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series AA Preferred Stock [Member] Series M [Member] Series NC Preferred Stock [Member] Series M Preferred Stock [Member] Equity Components [Axis] Preferred Stock Series A [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Contributed Capital [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Equity Line Agreement [Member] Legal Entity [Axis] Coventry Enterprises L L C [Member] Related Party, Type [Axis] David Koos [Member] Related Party Transaction [Axis] Related Party [Member] Bostonia Partners Inc [Member] Nonrelated Party [Member] Debt Instrument [Axis] Unsecured Promissory Note [Member] March 8, 2016 [Member] April 6, 2016 [Member] October 31, 2016 [Member] May 5, 2017 [Member] December 20, 2017 [Member] October 3, 2017 [Member] September 30, 2018 [Member] Zander Therapeutics [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement [Table] Statement [Line Items] ASSETS CURRENT ASSETS Cash Accounts Receivable, Related Party Note Receivable, Related Party Prepaid Expenses Prepaid Rent Total Current Assets OTHER ASSETS Investment Securities, Related Party Total Other Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable Notes Payable Accrued payroll taxes Accrued Interest Accrued Payroll Other Accrued Expenses Bank Overdraft Due to Investor Unearned Income Unearned Income ( Related Party) Derivative Liability Convertible Notes Payable Less unamortized discount Convertible Notes Payable, Related Parties Less unamortized discount Total Current Liabilities Long Term Liabilities: Convertible Notes Payable, Related Parties Less unamortized discount Notes Payable Total Long Term Liabilities Total Liabilities STOCKHOLDERS' EQUITY (DEFICIT) Common Stock ($.0001 par value); 5,800,000 shares authorized and 3,750,565 issued and outstanding as of December 31, 2023 and 3,506,366 shares issued and outstanding as of September 30,2023. Preferred stock, value Additional Paid in capital Contributed Capital Retained Earnings (Deficit) Total Stockholders' Equity (Deficit) TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT) Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares outstanding Income Statement [Abstract] REVENUES Revenues Revenues, Related Party TOTAL REVENUES COST AND EXPENSES Research and Development General and Administrative Consulting and Professional Fees Rent Total Costs and Expenses OPERATING INCOME (LOSS) OTHER INCOME & (EXPENSES) Interest Expense Interest Expense attributable to Amortrization of Discount Unrealized Gain ( Loss) on sale of Investment Securites Derivative Income (Expense) Gain (Loss) on Extinguishment Convertible Debt TOTAL OTHER INCOME (EXPENSE) NET INCOME (LOSS) NET INCOME (LOSS) attributable to common shareholders EARNINGS (LOSS) PER SHARE, BASIC EARNINGS (LOSS) PER SHARE, FULLY DILUTED WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, FULLY DILUTED Beginning balance, value Beginning balance, shares Preferred Shares Issued for Nonemployee Services Preferred Shares Issued for Nonemployee Services, shares Preferred Shares Issued for Debt Preferred Shares Issued for Debt, shares Preferred Shares Issued for Interest Preferred Shares Issued for Interest, shares Common Shares Issued For Interest Common Shares Issued For Interest, shares Preferred Shares Issued for Nonemployee Services Preferred Shares Issued for Nonemployee Services, shares Common Shares issued for Cash Common Shares issued for Cash, shares Common Shares issued for Cash Common Shares issued for Cash, shares Common Shares issued for Cash Common Shares issued for Cash, shares Common Shares issued for Cash Common Shares issued for Cash, shares EX-101.PRE 10 rgbp-20231231_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover	3 Months Ended
Cover	Dec. 31, 2023 shares
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--09-30
Entity File Number	333-191725
Entity Registrant Name	REGEN BIOPHARMA INC
Entity Central Index Key	0001589150
Entity Tax Identification Number	45-5192997
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	4700 Spring Street
Entity Address, Address Line Two	St 304
Entity Address, City or Town	La Mesa
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91942
City Area Code	619
Local Phone Number	722-5505
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	3,750,565

XML 12 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Sep. 30, 2023
CURRENT ASSETS
Cash	$ 124,497	$ 121,037
Accounts Receivable, Related Party	12,298	0
Note Receivable, Related Party		0
Prepaid Expenses		0
Prepaid Rent	5,000	10,000
Total Current Assets	141,795	131,037
OTHER ASSETS
Investment Securities, Related Party	17,733	222,580
Total Other Assets	17,733	222,580
TOTAL ASSETS	159,528	353,617
Current Liabilities:
Accounts payable	44,183	29,674
Notes Payable	49,210	95,710
Accrued payroll taxes	4,241	4,241
Accrued Interest	360,353	342,588
Accrued Payroll	1,256,630	1,256,630
Other Accrued Expenses	41,423	41,423
Bank Overdraft	1,000	1,000
Due to Investor	20,000	20,000
Unearned Income	1,560,091	1,591,731
Unearned Income ( Related Party)	0	15,126
Derivative Liability	1,400,000	1,400,000
Convertible Notes Payable Less unamortized discount	499,880	499,880
Convertible Notes Payable, Related Parties Less unamortized discount	10,000	10,000
Total Current Liabilities	5,247,010	5,308,003
Long Term Liabilities:
Convertible Notes Payable, Related Parties Less unamortized discount
Notes Payable	153,981	149,614
Total Long Term Liabilities	153,981	149,614
Total Liabilities	5,400,991	5,457,617
STOCKHOLDERS' EQUITY (DEFICIT)
Common Stock ($.0001 par value); 5,800,000 shares authorized and 3,750,565 issued and outstanding as of December 31, 2023 and 3,506,366 shares issued and outstanding as of September 30,2023.	376	352
Preferred stock, value
Additional Paid in capital	14,120,412	13,908,141
Contributed Capital	736,326	736,326
Retained Earnings (Deficit)	(20,098,623)	(19,748,863)
Total Stockholders' Equity (Deficit)	(5,241,463)	(5,104,000)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	159,528	353,617
Series A Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, value	40	40
Series AA Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, value	0	0
Series M [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, value	3	3
Series NC Preferred Stock [Member]
STOCKHOLDERS' EQUITY (DEFICIT)
Preferred stock, value	$ 2	$ 2

XML 13 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2023	Sep. 30, 2023
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	5,800,000	5,800,000
Common stock, shares issued	3,750,565	3,506,366
Common stock, shares outstanding	3,750,565	3,506,366
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	800,000,000	800,000,000
Series A Preferred Stock [Member]
Preferred stock, shares authorized	739,000,000	739,000,000
Preferred stock, shares outstanding	409,551	409,551
Series AA Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares outstanding	34	34
Series M Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	60,000,000	60,000,000
Preferred stock, shares outstanding	29,338	29,338
Series NC Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares outstanding	15,007	15,007

XML 14 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
REVENUES
Revenues	$ 31,640	$ 31,640
Revenues, Related Party	27,425	27,425
TOTAL REVENUES	59,065	59,065
COST AND EXPENSES
Research and Development	47,528	95,513
General and Administrative	12,419	8,738
Consulting and Professional Fees	106,900	403,680
Rent	15,000	15,000
Total Costs and Expenses	181,846	522,931
OPERATING INCOME (LOSS)	(122,782)	(463,867)
OTHER INCOME & (EXPENSES)
Interest Expense	(17,764)	(17,359)
Interest Expense attributable to Amortrization of Discount	(4,367)	0
Unrealized Gain ( Loss) on sale of Investment Securites	(204,847)	0
Derivative Income (Expense)	0	2,115,806
Gain (Loss) on Extinguishment Convertible Debt	0	1,150
TOTAL OTHER INCOME (EXPENSE)	(226,978)	2,099,597
NET INCOME (LOSS)	(349,760)	1,635,730
NET INCOME (LOSS) attributable to common shareholders	$ (349,760)	$ 1,448,439

XML 15 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (Parenthetical) - $ / shares	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
EARNINGS (LOSS) PER SHARE, BASIC	$ (0.10)	$ 0.4500
EARNINGS (LOSS) PER SHARE, FULLY DILUTED	$ (0.10)	$ 0.4500
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC	3,596,027	3,360,540
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, FULLY DILUTED	3,596,027	3,360,540

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY (DEFICIT) (unaudited) - USD ($)	Preferred Stock Series A [Member]	Series AA Preferred Stock [Member]	Series NC Preferred Stock [Member]	Common Stock [Member]	Series M Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Contributed Capital [Member]	Total
Beginning balance, value at Sep. 30, 2022
Beginning balance, shares at Sep. 30, 2022
Preferred Shares Issued for Nonemployee Services	$ 1					299,999			300,000
Preferred Shares Issued for Nonemployee Services, shares	6,667
Preferred Shares Issued for Debt	$ 7					761,493			761,500
Preferred Shares Issued for Debt, shares	70,114
Preferred Shares Issued for Interest	$ 4					380,258			380,262
Preferred Shares Issued for Interest, shares	35,012
Common Shares Issued For Interest				$ 1		25,368			25,369
Common Shares Issued For Interest, shares				11,279
Preferred Shares Issued for Nonemployee Services	$ 0					48,372			48,372
Preferred Shares Issued for Nonemployee Services, shares	1,112
Net Income							1,635,730		1,635,730
Ending balance, value at Dec. 31, 2022	$ 40	$ 0		$ 337	$ 3	13,648,107	(19,269,640)	736,326	(4,884,827)
Ending balance, shares at Dec. 31, 2022	405,958	34	7	3,366,165	29,338
Beginning balance, value at Sep. 30, 2023	$ 40	$ 0	$ 2	$ 352	$ 3	13,908,141	(19,748,863)	736,326	(5,104,000)
Beginning balance, shares at Sep. 30, 2023	409,551	34	15,007	3,506,366	29,338
Common Shares issued for Cash				$ 2		22,724			22,726
Common Shares issued for Cash, shares				16,710
Common Shares issued for Cash				$ 4		46,088			46,091
Common Shares issued for Cash, shares				35,785
Common Shares issued for Cash				$ 3		38,202			38,205
Common Shares issued for Cash, shares				31,732
Common Shares issued for Cash				$ 3		32,626			32,629
Common Shares issued for Cash, shares				33,989
Common Shares issued for Cash				$ 4		38,097			38,101
Common Shares issued for Cash, shares				43,297
Common Shares issued for Cash				$ 8		34,535			34,543
Common Shares issued for Cash, shares				82,686
Net Income							(349,760)		(349,760)
Ending balance, value at Dec. 31, 2023	$ 40	$ 0		$ 376	$ 3	$ 14,120,412	$ (20,098,623)	$ 736,326	$ (5,241,463)
Ending balance, shares at Dec. 31, 2023	409,551	34	15,007	3,750,565	29,338

XML 17 R7.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (349,760)	$ 1,635,730
Adjustments to reconcile net Income to net cash
Preferred Stock issued as compensation		348,372
Increase (Decrease) in Interest expense attributable to amortization of Discount	4,367
Increase (Decrease) in Accounts Payable	14,509	2,240
(Increase) Decrease in Accounts Receivable	(12,298)	122,575
Increase (Decrease) in accrued Expenses	17,765	17,359
(Increase) Decrease in Prepaid Expenses	5,000	11,856
Increase(Decrease) in Contributed Capital
Increase ( Decrease) in Derivative Expense		(2,115,806)
Increase ( Decrease) in Unearned Income	(46,767)	(31,640)
(Gain) Loss on forgiveness of Debt		(1,150)
Unrealized Loss(Gain) on Investment Securities	204,847
Net Cash Provided by (Used in) Operating Activities	(162,336)	(10,463)
CASH FLOWS FROM FINANCING ACTIVITIES
Increase (Decrease) in Convertible Notes Payable
Increase (Decrease) in Notes Payable	(46,500)	0
Increase ( Decrease) in Common Stock issued for cash	212,297	0
Net Cash Provided by (Used in) Financing Activities	165,797
Net Increase (Decrease) in Cash	3,460	(10,463)
Cash at Beginning of Period	121,037	51,204
Cash at End of Period	124,497	40,741
Supplemental Disclosure of Noncash investing and financing activities:
Common shares Issued for Debt
Preferred Shares Issued for Debt		761,500
Cash Paid for Interest
Common shares Issued for Interest		25,269
Preferred Shares issued for Interest		$ 380,262

XML 18 R8.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The Company was organized April 24, 2012 under the laws of the State of Nevada

A. BASIS OF ACCOUNTING

B. PRINCIPLES OF CONSOLIDATION


Schedule of Derivative liability
Risk Free Interest Rate	5.29	%
Expected Term	(2.78) – (3.41) Yrs
Expected Volatility	932.98	%
Expected Dividends

H. INCOME TAXES

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31, 2022 and December 31, 2023.

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

L. REVENUE RECOGNITION

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

XML 19 R9.htm IDEA: XBRL DOCUMENT

RECENT ACCOUNTING PRONOUNCEMENTS

3 Months Ended

Dec. 31, 2023

Accounting Changes and Error Corrections [Abstract]

RECENT ACCOUNTING PRONOUNCEMENTS

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS

The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors.

Any additional amounts the reporting entity expects to pay on behalf of its co-obligors.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org//250/tableOfContent

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

+ Details

XML 20 R10.htm IDEA: XBRL DOCUMENT

GOING CONCERN

3 Months Ended

Dec. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GOING CONCERN

NOTE 3. GOING CONCERN

The Company issued Coventry 125,000 shares of its Common Stock in connection with the Equity Line Agreement.

Coventry has agreed that:

(a)

for so long as the market price of the Company’s common stock is above $1.25 per share and

(b)

the Company is in full compliance with all agreements entered into with Coventry and

(c)

During the quarter ended December 31, 2023 the Company issued 244,199 common shares pursuant to the Equity Line Agreement for aggregate cash consideration of $212,296.

XML 21 R11.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE

3 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

NOTES PAYABLE

NOTE 4. NOTES PAYABLE

(a) RELATED PARTY

Schedule of notes payable related party
	As of December 31, 2023
David Koos	$	710
Total:	$	710

$710 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

(b) NON RELATED PARTY As of December 31, 2023


Bostonia Partners, Inc.	$	48,500
Coventry Enterprises LLC	$	175,000
Total:	$	223,500

$48,500 lent to the Company by Bostonia Partners, Inc is due and payable on March 10, 2024 and bears simple interest at a rate of 10% per annum.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE

3 Months Ended

Dec. 31, 2023

Convertible Notes Payable

CONVERTIBLE NOTES PAYABLE

NOTE 5. CONVERTIBLE NOTES PAYABLE

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

As of December 31, 2023 $100,000 of the principal amount of the Note remains outstanding.

Upon closing of a Transaction Event the Lender shall receive 0.10% (one tenth of one percent) of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event.

“Transaction Event” shall mean either of:

(a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

As of December 31, 2023 $50,000 of the principal amount of the Note remains outstanding.

The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $18.75 per share.

As of December 31, 2023 $50,000 of the principal amount of the Note remains outstanding.

(iii) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31, 2023 $200,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $800,000 was recognized by the Company as of December 31, 2023.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31, 2023 $100,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $400,000 was recognized by the Company as of December 31, 2023.

(iv) One day subsequent to a “Transaction Event”)

Transaction Event” shall mean either of:

(a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party

(v) That date which is twenty four (24) months subsequent to the date of execution of this Note.

The warrants shall be exercisable:

As of December 31, 2023, $50,000 of the principal amount of the Note remains outstanding.

The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $200,000 was recognized by the Company as of December 31, 2023.

As of December 31, 2023, 10,000 of the principal amount of the Note remains outstanding.

Zander and Regen are under common control. Zander Therapeutics, Inc. is the sole licensee of Regen’s NR2F6 intellectual property for veterinary applications.

XML 23 R13.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

3 Months Ended

Dec. 31, 2023

RELATED PARTY TRANSACTIONS

NOTE 6. RELATED PARTY TRANSACTIONS

The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander.

The Agreement may be terminated by The Company:

The Agreement may be terminated by either party in the event of a material breach by the other party.

On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby:

2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement.

3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement.

No actions were taken by any of the parties to enforce the terms of the Agreement.

On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be:

a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return

Zander and Regen are under common control.

As of December 31, 2023, $10,000 of the principal amount of the Note remains outstanding.

On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of :

a) Reviewing existing publications on research being conducted on Checkpoint NR2F6.

b) Identifying the most promising applications for the Company’s technology

c) Drafting a “white paper” on results for 1(b)

d) Making introductions to known experts in appropriate fields identified in 1(b).

BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY

3 Months Ended

Dec. 31, 2023

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 7. STOCKHOLDERS’ EQUITY

The stockholders’ equity section of the Company contains the following classes of capital stock as of December 31, 2023:

Common stock, $ 0.0001 par value; 5,800,000 shares authorized: 3,750,565 shares issued and outstanding.

Series AA Preferred Stock

Series A Preferred Stock

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 25 R15.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARTY

3 Months Ended

Dec. 31, 2023

Investment Securities Related Party

INVESTMENT SECURITIES, RELATED PARTY

NOTE 8. INVESTMENT SECURITIES, RELATED PARTY

On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc.


Fair Value of Intellectual Property	$	300,000
Prepaid Expenses		65,661
Due from Employee		0
Note Receivable		40000
Accrued Interest Receivable		35,000
Investment Securities		258,255
Convertible Note Receivable		10,000
Accounts Payable		30,563
Notes Payable		400,000
Accrued Expenses Related Parties		162,011
Notes Payable Related Party		0
Accrued Expenses		647,072
Enterprise Value		1,948,562
Less: Total Debt		(1,239,646	)
Portion of Enterprise Value Attributable to Shareholders	$	708,916
Fair Value per Shares	$	0.02

The abovementioned constitute the Company’s sole related party investment securities as of December 31, 2023.

As of December 31, 2023:

	Schedule of comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2023
$	5,741	$	6,496	$	755	$	(81,112)

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss		Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2023
$	13,124	$	11,238	$	(1,866)	$	(123,733)

XML 26 R16.htm IDEA: XBRL DOCUMENT

STOCK TRANSACTIONS

3 Months Ended

Dec. 31, 2023

Stock Transactions

STOCK TRANSACTIONS

NOTE 9. STOCK TRANSACTIONS

On October 13 2023 the Company issued 16,710 common shares for cash consideration of $22,726.

On October 27 2023 the Company issued 35,785 common shares for cash consideration of $46,091.

On November 10, 2023 the Company issued 31,732 common shares for cash consideration of $38,205.

On November 27, 2023 the Company issued 33,989 common shares for cash consideration of $32,629.

On December 11 2023 the Company issued 43,297 common shares for cash consideration of $38,101.

On December 20, 2023 the Company issued 82,686 common shares for cash consideration of $34,543.

XML 27 R17.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Dec. 31, 2023

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 10. SUBSEQUENT EVENTS

On January 3, 2024 the Company issued 94,883 common shares for cash consideration of $39,638.

On January 10, 2024 the Company issued 82,643 common shares for cash consideration of $39,638.

XML 28 R18.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

BASIS OF ACCOUNTING

A. BASIS OF ACCOUNTING

PRINCIPLES OF CONSOLIDATION

B. PRINCIPLES OF CONSOLIDATION


Schedule of Derivative liability
Risk Free Interest Rate	5.29	%
Expected Term	(2.78) – (3.41) Yrs
Expected Volatility	932.98	%
Expected Dividends

INCOME TAXES

H. INCOME TAXES

The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established.

Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

BASIC EARNINGS (LOSS) PER SHARE

I. BASIC EARNINGS (LOSS) PER SHARE

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

ADVERTISING

J. ADVERTISING

Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31, 2022 and December 31, 2023.

NOTES RECEIVABLE

K. NOTES RECEIVABLE

Notes receivable are stated at cost, less impairment, if any.

REVENUE RECOGNITION

L. REVENUE RECOGNITION

INTEREST RECEIVABLE

M. INTEREST RECEIVABLE

Interest receivable is stated at cost, less impairment, if any.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Dec. 31, 2023

Accounting Policies [Abstract]

Schedule of Derivative liability


Schedule of Derivative liability
Risk Free Interest Rate	5.29	%
Expected Term	(2.78) – (3.41) Yrs
Expected Volatility	932.98	%
Expected Dividends

XML 30 R20.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Tables)

3 Months Ended

Dec. 31, 2023

Debt Disclosure [Abstract]

Schedule of notes payable related party

Schedule of notes payable related party
	As of December 31, 2023
David Koos	$	710
Total:	$	710

Schedule of notes payable non related party


Bostonia Partners, Inc.	$	48,500
Coventry Enterprises LLC	$	175,000
Total:	$	223,500

XML 31 R21.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARTY (Tables)

3 Months Ended

Dec. 31, 2023

Investment Securities Related Party


Fair Value of Intellectual Property	$	300,000
Prepaid Expenses		65,661
Due from Employee		0
Note Receivable		40000
Accrued Interest Receivable		35,000
Investment Securities		258,255
Convertible Note Receivable		10,000
Accounts Payable		30,563
Notes Payable		400,000
Accrued Expenses Related Parties		162,011
Notes Payable Related Party		0
Accrued Expenses		647,072
Enterprise Value		1,948,562
Less: Total Debt		(1,239,646	)
Portion of Enterprise Value Attributable to Shareholders	$	708,916
Fair Value per Shares	$	0.02

Schedule of comprehensive income

	Schedule of comprehensive income
470,588 Common Shares of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Gains		Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2023
$	5,741	$	6,496	$	755	$	(81,112)

725,000 Series M Preferred of Zander Therapeutics, Inc.

	Basis		Fair Value		Total Unrealized Loss		Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2023
$	13,124	$	11,238	$	(1,866)	$	(123,733)

XML 32 R22.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	3 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Risk Free Interest Rate	5.29%
Expected Volatility	932.98%
Minimum [Member]
Property, Plant and Equipment [Line Items]
Expected Term	2 years 9 months 10 days
Maximum [Member]
Property, Plant and Equipment [Line Items]
Expected Term	3 years 4 months 28 days

XML 33 R23.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Deferred tax assets valuation allowance, percent	100.00%
Advertising expenses	$ 0	$ 0

XML 34 R24.htm IDEA: XBRL DOCUMENT

GOING CONCERN (Details Narrative) - USD ($)		3 Months Ended	140 Months Ended
GOING CONCERN (Details Narrative) - USD ($)	Sep. 12, 2023	Dec. 31, 2023	Dec. 31, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Net loss since inception			$ 20,098,623
Common stock equals percentage	80.00%
Common stock requested percentage	200.00%
Average daily traded value	$ 250,000
Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share price	$ 1.25
Common Stock [Member] \| Coventry Enterprises L L C [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Share price	$ 1.50
Resale of stock, shares	10,000
Equity Line Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares purchased, value	$ 10,000,000
Common stock, par value	$ 0.0001
Equity Line Agreement [Member] \| Common Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of shares issued, shares	125,000	244,199
Resale of stock, shares	1,126,954
Number of shares issued, value		$ 212,296

XML 35 R25.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Notes payable	$ 49,210	$ 95,710
Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable	710
David Koos [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable	710
David Koos [Member] \| Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Notes payable	$ 710

XML 36 R26.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details 1) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Notes payable	$ 49,210	$ 95,710
Nonrelated Party [Member]
Notes payable	223,500
Bostonia Partners Inc [Member] \| Nonrelated Party [Member]
Notes payable	48,500
Coventry Enterprises L L C [Member] \| Nonrelated Party [Member]
Notes payable	$ 175,000

XML 37 R27.htm IDEA: XBRL DOCUMENT

NOTES PAYABLE (Details Narrative) - USD ($)		3 Months Ended
NOTES PAYABLE (Details Narrative) - USD ($)	Sep. 12, 2023	Dec. 31, 2023	Sep. 30, 2023
Short-Term Debt [Line Items]
Notes payable		$ 49,210	$ 95,710
Unsecured Promissory Note [Member]
Short-Term Debt [Line Items]
Principal amount	$ 175,000
Original issue discount	$ 26,250
Principal amount rate percentage	10.00%
Guaranteed interest	$ 26,250
Guaranteed interest on principal amount due	$ 28,750
Maturity date	Mar. 12, 2025
Related Party [Member]
Short-Term Debt [Line Items]
Notes payable		710
Nonrelated Party [Member]
Short-Term Debt [Line Items]
Notes payable		223,500
Nonrelated Party [Member] \| Bostonia Partners Inc [Member]
Short-Term Debt [Line Items]
Notes payable		$ 48,500
Interest rate		10.00%
David Koos [Member]
Short-Term Debt [Line Items]
Notes payable		$ 710
David Koos [Member] \| Related Party [Member]
Short-Term Debt [Line Items]
Notes payable		$ 710
Interest rate		15.00%

XML 38 R28.htm IDEA: XBRL DOCUMENT

CONVERTIBLE NOTES PAYABLE (Details Narrative)	Dec. 31, 2023 USD ($) $ / shares
March 8, 2016 [Member]
Short-Term Debt [Line Items]
Convertible notes payable amount	$ 100,000
Cash issued for convertible note	$ 100,000
Annual percentage rate	8.00%
Conversion price \| $ / shares	$ 150
Outstanding principal amount	$ 100,000
April 6, 2016 [Member]
Short-Term Debt [Line Items]
Convertible notes payable amount	50,000
Cash issued for convertible note	$ 50,000
Annual percentage rate	8.00%
Conversion price \| $ / shares	$ 150
Outstanding principal amount	$ 50,000
October 31, 2016 [Member]
Short-Term Debt [Line Items]
Convertible notes payable amount	50,000
Cash issued for convertible note	$ 50,000
Annual percentage rate	10.00%
Conversion price \| $ / shares	$ 18.75
Outstanding principal amount	$ 50,000
May 5, 2017 [Member]
Short-Term Debt [Line Items]
Convertible notes payable amount	200,000
Cash issued for convertible note	$ 200,000
Annual percentage rate	10.00%
Conversion price \| $ / shares	$ 75
Outstanding principal amount	$ 200,000
Derivative liability	800,000
December 20, 2017 [Member]
Short-Term Debt [Line Items]
Convertible notes payable amount	100,000
Cash issued for convertible note	$ 100,000
Annual percentage rate	10.00%
Conversion price \| $ / shares	$ 37.50
Outstanding principal amount	$ 100,000
Derivative liability	400,000
October 3, 2017 [Member]
Short-Term Debt [Line Items]
Convertible notes payable amount	50,000
Cash issued for convertible note	$ 50,000
Annual percentage rate	10.00%
Conversion price \| $ / shares	$ 37.5
Outstanding principal amount	$ 50,000
Derivative liability	200,000
September 30, 2018 [Member]
Short-Term Debt [Line Items]
Convertible notes payable amount	350,000
Cash issued for convertible note	$ 350,000
Annual percentage rate	10.00%
Outstanding principal amount	$ 10,000

XML 39 R29.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Related Party Transaction [Line Items]
Due to related party	$ 49,210	$ 95,710
David Koos [Member]
Related Party Transaction [Line Items]
Due to related party	710
Due to related party carrying amount	710
September 30, 2018 [Member]
Related Party Transaction [Line Items]
Principal amount	350,000
Outstanding principal amount	$ 10,000

XML 40 R30.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares	Dec. 31, 2023	Sep. 30, 2023
Class of Stock [Line Items]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	5,800,000	5,800,000
Common stock, shares issued	3,750,565	3,506,366
Common stock, shares outstanding	3,750,565	3,506,366
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	800,000,000	800,000,000
Series AA Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	600,000	600,000
Preferred stock, shares issued	34
Preferred stock, shares outstanding	34	34
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	739,000,000	739,000,000
Preferred stock, shares outstanding	409,551	409,551
Series M Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	60,000,000	60,000,000
Preferred stock, shares outstanding	29,338	29,338
Series NC Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares outstanding	15,007	15,007

XML 41 R31.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARTY (Details) - USD ($)	Dec. 31, 2023	Sep. 30, 2023
Accounts Payable	$ 44,183	$ 29,674
Series M [Member] \| Zander Therapeutics [Member]
Fair Value of Intellectual Property	300,000
Prepaid Expenses	65,661
Due from Employee	0
Note Receivable	40,000
Accrued Interest Receivable	35,000
Investment Securities	258,255
Convertible Note Receivable	10,000
Accounts Payable	30,563
Notes Payable	400,000
Accrued Expenses Related Parties	162,011
Notes Payable Related Party	0
Accrued Expenses	647,072
Enterprise Value	1,948,562
Less: Total Debt	(1,239,646)
Portion of Enterprise Value Attributable to Shareholders	$ 708,916
Fair Value per Shares	$ 0.02

XML 42 R32.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARTY (Details 1) - Zander Therapeutics [Member]	3 Months Ended
	Dec. 31, 2023 USD ($)
Common Stock [Member]
Investment securities, Basis	$ 5,741
Investment securities, Fair value	6,496
Investment securities, Total unrealized gains	755
Investment securities, Net unrealized gain or (loss) realized	(81,112)
Series M [Member]
Investment securities, Basis	13,124
Investment securities, Fair value	11,238
Investment securities, Total unrealized gains	(1,866)
Investment securities, Net unrealized gain or (loss) realized	$ (123,733)

XML 43 R33.htm IDEA: XBRL DOCUMENT

INVESTMENT SECURITIES, RELATED PARTY (Details Narrative) - Zander Therapeutics [Member] - USD ($)			3 Months Ended
	Nov. 29, 2018	Jun. 11, 2018	Dec. 31, 2023
Number of shares issued for dividends		470,588	470,588
Series M Preferred Stock [Member]
Shares issued in satisfaction of prepaid rent and accrued interest, shares	725,000		725,000
Shares issued in satisfaction of prepaid rent and accrued interest, value	$ 13,124

XML 44 R34.htm IDEA: XBRL DOCUMENT

STOCK TRANSACTIONS (Details Narrative) - Common Stock [Member] - USD ($)	Dec. 20, 2023	Dec. 11, 2023	Nov. 27, 2023	Nov. 10, 2023	Oct. 27, 2023	Oct. 13, 2023
Common stock, shares issued	82,686	43,297	33,989	31,732	35,785	16,710
Cash consideration	$ 34,543	$ 38,101	$ 32,629	$ 38,205	$ 46,091	$ 22,726

XML 45 R35.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)	Jan. 10, 2024	Jan. 03, 2024
Subsequent Event [Line Items]
Common stock, shares issued	82,643	94,883
Cash consideration	$ 39,638	$ 39,638

XML 46 rgbp123123form10q_htm.xml IDEA: XBRL DOCUMENT 0001589150 2023-10-01 2023-12-31 0001589150 2023-12-31 0001589150 2023-09-30 0001589150 us-gaap:SeriesAPreferredStockMember 2023-12-31 0001589150 us-gaap:SeriesAPreferredStockMember 2023-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2023-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2023-09-30 0001589150 RGBP:SeriesMMember 2023-12-31 0001589150 RGBP:SeriesMMember 2023-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2023-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2023-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2023-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2023-09-30 0001589150 2022-10-01 2022-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2023-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2023-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2023-09-30 0001589150 us-gaap:CommonStockMember 2023-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2023-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001589150 us-gaap:RetainedEarningsMember 2023-09-30 0001589150 RGBP:ContributedCapitalMember 2023-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2022-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2022-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2022-09-30 0001589150 us-gaap:CommonStockMember 2022-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2022-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001589150 us-gaap:RetainedEarningsMember 2022-09-30 0001589150 RGBP:ContributedCapitalMember 2022-09-30 0001589150 2022-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2023-10-01 2023-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2023-10-01 2023-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2023-10-01 2023-12-31 0001589150 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2023-10-01 2023-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001589150 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001589150 RGBP:ContributedCapitalMember 2023-10-01 2023-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-10-01 2022-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-10-01 2022-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-10-01 2022-12-31 0001589150 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-10-01 2022-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001589150 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001589150 RGBP:ContributedCapitalMember 2022-10-01 2022-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2023-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2023-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2023-12-31 0001589150 us-gaap:CommonStockMember 2023-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2023-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001589150 us-gaap:RetainedEarningsMember 2023-12-31 0001589150 RGBP:ContributedCapitalMember 2023-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-12-31 0001589150 us-gaap:CommonStockMember 2022-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001589150 us-gaap:RetainedEarningsMember 2022-12-31 0001589150 RGBP:ContributedCapitalMember 2022-12-31 0001589150 2022-12-31 0001589150 srt:MinimumMember 2023-10-01 2023-12-31 0001589150 srt:MaximumMember 2023-10-01 2023-12-31 0001589150 2012-04-24 2023-12-31 0001589150 RGBP:EquityLineAgreementMember 2023-09-11 2023-09-12 0001589150 RGBP:EquityLineAgreementMember 2023-09-12 0001589150 2023-09-11 2023-09-12 0001589150 us-gaap:CommonStockMember RGBP:EquityLineAgreementMember 2023-09-11 2023-09-12 0001589150 us-gaap:CommonStockMember 2023-09-12 0001589150 us-gaap:CommonStockMember RGBP:CoventryEnterprisesLLCMember 2023-09-12 0001589150 us-gaap:CommonStockMember RGBP:CoventryEnterprisesLLCMember 2023-09-11 2023-09-12 0001589150 us-gaap:CommonStockMember RGBP:EquityLineAgreementMember 2023-10-01 2023-12-31 0001589150 us-gaap:RelatedPartyMember RGBP:DavidKoosMember 2023-12-31 0001589150 us-gaap:RelatedPartyMember 2023-12-31 0001589150 us-gaap:RelatedPartyMember RGBP:DavidKoosMember 2023-10-01 2023-12-31 0001589150 us-gaap:NonrelatedPartyMember RGBP:BostoniaPartnersIncMember 2023-12-31 0001589150 us-gaap:NonrelatedPartyMember RGBP:BostoniaPartnersIncMember 2023-10-01 2023-12-31 0001589150 RGBP:UnsecuredPromissoryNoteMember 2023-09-11 2023-09-12 0001589150 us-gaap:NonrelatedPartyMember RGBP:CoventryEnterprisesLLCMember 2023-12-31 0001589150 us-gaap:NonrelatedPartyMember 2023-12-31 0001589150 RGBP:March82016Member 2023-12-31 0001589150 RGBP:April62016Member 2023-12-31 0001589150 RGBP:October312016Member 2023-12-31 0001589150 RGBP:May52017Member 2023-12-31 0001589150 RGBP:December202017Member 2023-12-31 0001589150 RGBP:October32017Member 2023-12-31 0001589150 RGBP:September302018Member 2023-12-31 0001589150 RGBP:DavidKoosMember 2023-12-31 0001589150 RGBP:ZanderTherapeuticsMember 2018-06-10 2018-06-11 0001589150 RGBP:SeriesMPreferredStockMember RGBP:ZanderTherapeuticsMember 2018-11-28 2018-11-29 0001589150 RGBP:ZanderTherapeuticsMember 2023-10-01 2023-12-31 0001589150 RGBP:SeriesMPreferredStockMember RGBP:ZanderTherapeuticsMember 2023-10-01 2023-12-31 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2023-12-31 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2023-12-31 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2023-10-01 2023-12-31 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2023-10-01 2023-12-31 0001589150 us-gaap:CommonStockMember 2023-10-13 0001589150 us-gaap:CommonStockMember 2023-10-27 0001589150 us-gaap:CommonStockMember 2023-11-10 0001589150 us-gaap:CommonStockMember 2023-11-27 0001589150 us-gaap:CommonStockMember 2023-12-11 0001589150 us-gaap:CommonStockMember 2023-12-20 0001589150 us-gaap:SubsequentEventMember 2024-01-03 0001589150 us-gaap:SubsequentEventMember 2024-01-10 iso4217:USD shares iso4217:USD shares pure false --09-30 2024 Q1 0001589150

10-Q true 2023-12-31 false 333-191725 REGEN BIOPHARMA INC NV 45-5192997 4700 Spring Street St 304 La Mesa CA 91942 619 722-5505 Yes No Non-accelerated Filer true false 3750565 false

124497

121037

12298

5000

10000

141795

131037

17733 222580

17733

222580

159528

353617

44183

29674

49210

95710

4241

360353

342588

1256630 1256630 41423 41423

1000

20000 20000 1560091 1591731 0 15126

1400000

499880

10000 10000

5247010

5308003

153981

149614

153981

149614

5400991

5457617

0.0001

5800000

3750565

3506366

376

352

0.0001

800000000

739000000

409551

0.0001

600000

0.0001

60000000

29338

60000000

29338

0.0001

20000

15007

14120412

13908141

736326

-20098623

-19748863

-5241463

-5104000

159528

353617

31640

27425 27425 59065 59065

47528

95513

12419

8738

106900

403680

15000

181846

522931

-122782

-463867

17764

17359

-4367 0

-204847

2115806

1150

-226978

2099597

-349760

1635730

-349760

1448439

-0.10

0.4500

3596027

3360540

409551

15007

3506366

352

29338

13908141

-19748863

736326

-5104000

16710 2 22724 22726 35785 4 46088 46091 31732 3 38202 38205 33989 3 32626 32629 43297 4 38097 38101 82686 8 34535 34543

-349760

409551

15007

3750565

376

29338

14120412

-20098623

736326

-5241463

6667 1 299999 300000 70114 7 761493 761500 35012 4 380258 380262 11279 1 25368 25369 1112 0 48372 48372

1635730

405958

3366165

337

29338

13648107

-19269640

736326

-4884827

-349760

1635730

-348372

4367

14509

2240

12298

-122575

17765

17359

-5000

-11856

-2115806

-46767

-31640

1150 -204847

-162336

-10463

-46500

212297

165797

3460

-10463

121037

51204

124497

40741

761500 25269 380262

NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company was organized April 24, 2012 under the laws of the State of Nevada The Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company is currently engaged in actively identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications and immune cell suppression for autoimmune disease. The Company is in the early stages of development of its proposed products and therapies. The Company will be required to obtain approval from the FDA in order to market any of The Company’s products or therapies. No approval has been granted by the FDA for the marketing and sale of any of the Company’s products and therapies and no assurance may be given that any of the Company’s products or therapies will be granted such approval. The Company’s current plans include the development of regenerative medical applications up to the point of successful completion of Phase I and/ or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials. The Company can provide no assurance that the Company will be able to sell or license any product or that, if such product is sold or licensed, such sale or license will be on terms favorable to the Company. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of December 31, 2023 utilized the following inputs: <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zgcz37rnzVJ8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of Derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Risk Free Interest Rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">5.29</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Term</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20231231__srt--RangeAxis__srt--MinimumMember_zvEVuWQqMsI" title="Expected Term">2.78) – (<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20231231__srt--RangeAxis__srt--MaximumMember_z48By0lNBwBe" title="Expected Term">3.41) Yrs</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">932.98</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Dividends</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2023 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. J. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31, 2022 and December 31, 2023. K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any. L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company. M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.

B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of KCL Therapeutics, Inc., a Nevada corporation and wholly owned subsidiary of Regen. Significant inter-company transactions have been eliminated. The Company analyzes the conversion feature of Convertible Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model. The Black Scholes pricing model used to determine the Derivative Liability on convertible notes issued by the Company in which an embedded derivative is recognized as of December 31, 2023 utilized the following inputs: <table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zgcz37rnzVJ8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of Derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Risk Free Interest Rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">5.29</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Term</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20231231__srt--RangeAxis__srt--MinimumMember_zvEVuWQqMsI" title="Expected Term">2.78) – (<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20231231__srt--RangeAxis__srt--MaximumMember_z48By0lNBwBe" title="Expected Term">3.41) Yrs</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">932.98</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Dividends</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" id="xdx_882_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zgcz37rnzVJ8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of Derivative liability</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Risk Free Interest Rate</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right">5.29</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Term</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">(<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20231231__srt--RangeAxis__srt--MinimumMember_zvEVuWQqMsI" title="Expected Term">2.78) – (<span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20231001__20231231__srt--RangeAxis__srt--MaximumMember_z48By0lNBwBe" title="Expected Term">3.41) Yrs</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">932.98</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">%</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected Dividends</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

0.0529

P2Y9M10D

P3Y4M28D

9.3298

H. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes.” Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes”, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2023 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward. However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.

I. BASIC EARNINGS (LOSS) PER SHARE The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, “Earnings Per Share”, which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding.

J. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 for the quarters ended December 31, 2022 and December 31, 2023.

K. NOTES RECEIVABLE Notes receivable are stated at cost, less impairment, if any.

L. REVENUE RECOGNITION Sales of products and related costs of products sold are recognized when: (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred; (iii) the price is fixed or determinable; and (iv) collectability is reasonably assured. These terms are typically met upon the prepayment or invoicing and shipment of products. The Company determines the amount and timing of royalty revenue based on its contractual agreements with intellectual property licensees. The Company recognizes royalty revenue when earned under the terms of the agreements and when the Company considers realization of payment to be probable. Where royalties are based on a percentage of licensee sales of royalty-bearing products, the Company recognizes royalty revenue by applying this percentage to the Company’s estimate of applicable licensee sales. The Company bases this estimate on an analysis of each licensee’s sales results. Where warranted, revenue from licensees for contractual obligations such as License Initiation Fees are recognized upon satisfaction of all conditions required to be satisfied in order for that revenue to have been earned by the Company.

M. INTEREST RECEIVABLE Interest receivable is stated at cost, less impairment, if any.

NOTE 2. RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as “Development Stage Entities” (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity’s financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. As of the fiscal year ending September 30, 2019 the Company has adopted Accounting Standards Update 2014-09, Revenue from Contracts with Customers (Topic 606). The guidance in this Update supersedes the revenue recognition requirements in Topic 605, Revenue Recognition, and most industry-specific guidance throughout the Industry Topics of the Codification. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award’s grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements – Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity’s liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company adopted ASU 2016-01 as of the fiscal year ending September 30, 2019. In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity (“ASU 2020-06"), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity, and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the “if-converted” method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company’s current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company has adopted ASU 2020-06 as of the Fiscal Year ending September 30, 2022. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $20,098,623 during the period from April 24, 2012 (inception) through December 31, 2023. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. On September 12, 2023 the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Coventry Enterprises LLC ( “Coventry”) providing for an equity financing facility (the “Equity Line”). The Equity Line Agreement provides that upon the terms and subject to the conditions in the Equity Line Agreement, Coventry is committed to purchase up to Ten Million Dollars ($10,000,000) of shares of common stock, $0.0001 par value per share (the “Common Stock”), over the 36-month term of the Equity Line Agreement (the “Total Commitment”). Under the terms of the Equity Line Agreement, Coventry will not be obligated to purchase shares of Common Stock unless and until certain conditions are met, including but not limited to a Registration Statement on Form S-1 (the “Registration Statement”) becoming effective which registers Coventry’s resale of any Common Stock purchased by Coventry under the Equity Line. From time to time over the 36-month term of the Commitment Period ( as such term is defined in the Equity Line Agreement) the Company, in its sole discretion, may provide Coventry with a draw down notice (each, a “Draw Down Notice”), to purchase a specified number of shares of Common Stock (each, a “Draw Down Amount Requested”), subject to the limitations discussed below. The actual amount of proceeds the Company will receive pursuant to each Draw Down Notice (each, a “Draw Down Amount”) is to be determined by multiplying the Draw Down Amount Requested by the applicable purchase price. The purchase price of each share of Common Stock equals 80% of the lowest trading price of the Common Stock during the ten business days prior to the Draw Down Notice date (the “Pricing Period”). The maximum number of shares of Common Stock requested to be purchased pursuant to any single Draw Down Notice cannot exceed the lesser of (i) 200% of the Average Daily Traded Value ( as such term is defined in the Equity Line Agreement) during the ten business days immediately preceding the Drawdown Notice Date or (ii) $250,000. The Company is prohibited from delivering a Draw Down Notice if the sale of shares of Common Stock pursuant to the Draw Down Notice would cause the Company to issue and sell to Coventry or Coventry to acquire or purchase an aggregate number of shares of Common Stock that would result in Coventry beneficially owning more than 4.99% of the issued and outstanding shares of Common Stock of the Company. The Company issued Coventry <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230911__20230912__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zxDaRv7obST3" title="Number of shares issued, shares">125,000 shares of its Common Stock in connection with the Equity Line Agreement. Coventry has agreed that: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right">(a)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">for so long as the market price of the Company’s common stock is above $1.25 per share and</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right">(b)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">the Company is in full compliance with all agreements entered into with Coventry and</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"> <td style="font: 10pt Times New Roman, Times, Serif; width: 15pt; text-align: right">(c)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 5pt"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">and the Company has not issued any common shares at a per share price below $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20230912__dei--LegalEntityAxis__custom--CoventryEnterprisesLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zNEBxZiEMSPc" title="Share price">1.50, Coventry will agree to a leak out provision and will not sell more than <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230911__20230912__dei--LegalEntityAxis__custom--CoventryEnterprisesLLCMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z9vzIXzqhKqc" title="Resale of stock, shares">10,000 shares of the Commitment shares without permission from the Issuer.</td> </tr></table> In connection with the Equity Line Agreement the Company also entered into a Registration Rights Agreement, dated September 12, 2023 with Coventry (the “Registration Rights Agreement”), pursuant to which the Company agreed to register for resale under the Securities Act of 1933 shares issuable in accordance with the Equity Line Agreement as well as the aforementioned <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230911__20230912__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zhS1GLBDuCT6" title="Number of shares issued, shares">125,000 common shares issued in connection with the Equity Line Agreement in a Registration Statement to be filed with the Securities and Exchange Commission. Up to <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230911__20230912__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_z3YvOBOmrZTc" title="Resale of stock, shares">1,126,954 Shares of Common Stock were registered for resale under the Securities Act of 1933 pursuant to the Registration Rights Agreement. During the quarter ended December 31, 2023 the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20231001__20231231__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zbKb9jBdx2X1" title="Number of shares issued, shares">244,199 common shares pursuant to the Equity Line Agreement for aggregate cash consideration of $<span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20231001__20231231__us-gaap--TypeOfArrangementAxis__custom--EquityLineAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zH2eWfe2NfJe" title="Number of shares issued, value">212,296.

20098623

10000000

0.0001 0.80 2 250000

125000

1.25

1.50

10000

125000

1126954

244199

212296

NOTE 4. NOTES PAYABLE (a) RELATED PARTY <table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zwfoiU67ZFB2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of notes payable related party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">As of December 31, 2023</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">David Koos</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DavidKoosMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_z9oXuz5m3CDf" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes payable">710</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_z0Omh9BYOFhh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes payable">710</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> $<span id="xdx_904_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DavidKoosMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zZxgVL30kw27" title="Notes payable">710 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20231001__20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DavidKoosMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_zqVuVfWqB0L5" title="Interest rate">15% per annum. (b) NON RELATED PARTY As of December 31, 2023 <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zA8HTTKhJbA1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Schedule of notes payable non related party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">Bostonia Partners, Inc.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__dei--LegalEntityAxis__custom--BostoniaPartnersIncMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--NonrelatedPartyMember_zHE1SimiW9Bi" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes payable">48,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Coventry Enterprises LLC</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__dei--LegalEntityAxis__custom--CoventryEnterprisesLLCMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--NonrelatedPartyMember_zBAZtNYIXUVf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes payable">175,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionAxis__us-gaap--NonrelatedPartyMember_z8SrUI0azoi5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes payable">223,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> $<span id="xdx_906_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__dei--LegalEntityAxis__custom--BostoniaPartnersIncMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--NonrelatedPartyMember_zYtnzw8Xp2P3" title="Notes payable">48,500 lent to the Company by Bostonia Partners, Inc is due and payable on March 10, 2024 and bears simple interest at a rate of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20231001__20231231__dei--LegalEntityAxis__custom--BostoniaPartnersIncMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--NonrelatedPartyMember_zjKXLVy62Yj7" title="Interest rate">10% per annum. Effective September 12, 2023 Coventry Enterprises purchased a 10% unsecured promissory Note (the “Note”) from the Company in the principal amount of $175,000 of which $26,250 was retained by Coventry through an Original Issue Discount. The Note carries “Guaranteed Interest” on the principal amount at the rate of <span id="xdx_90D_eus-gaap--DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_dp_c20230911__20230912__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember_zQiLy9EWNOh3" title="Principal amount rate percentage">10% per annum for the eighteen-month term of the Note for an aggregate Guaranteed Interest $26,250. The Principal Amount and the Guaranteed Interest shall be due and payable in seven equal monthly payments of $<span id="xdx_90E_ecustom--GuaranteedInterestOnPrincipalAmountDue_c20230911__20230912__us-gaap--DebtInstrumentAxis__custom--UnsecuredPromissoryNoteMember_z8JHYOEbb965" title="Guaranteed interest on principal amount due">28,750 commencing on August 12, 2024 and continuing on the 12th day of each month thereafter until paid in full not later than March 12, 2025 (the “Maturity Date”). Upon an Event of Default (as such term is defined in the Note) the Note shall become convertible, in whole or in part, into shares of Common Stock at the option of the Holder at price per share equivalent to 90% of the lowest per-share trading price for the 20 Trading Days preceding a Conversion Date. Upon the event that while this Note has been outstanding for four months, the Company consummates another financing transaction or if the Company has an effective Regulation A Offering Statement then the Investor may choose to convert any amount up to the entire balance of the note including guaranteed interest into shares at the same offering price as the aforementioned financing transaction or the Regulation A Offering..

<table cellpadding="0" cellspacing="0" id="xdx_895_eus-gaap--ScheduleOfDebtTableTextBlock_zwfoiU67ZFB2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif">Schedule of notes payable related party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: center">As of December 31, 2023</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">David Koos</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DavidKoosMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_z9oXuz5m3CDf" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes payable">710</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_987_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionAxis__us-gaap--RelatedPartyMember_z0Omh9BYOFhh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes payable">710</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

710

0.15

<table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zA8HTTKhJbA1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Schedule of notes payable non related party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: left">Bostonia Partners, Inc.</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__dei--LegalEntityAxis__custom--BostoniaPartnersIncMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--NonrelatedPartyMember_zHE1SimiW9Bi" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Notes payable">48,500</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Coventry Enterprises LLC</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_982_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__dei--LegalEntityAxis__custom--CoventryEnterprisesLLCMember__us-gaap--RelatedPartyTransactionAxis__us-gaap--NonrelatedPartyMember_zBAZtNYIXUVf" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes payable">175,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Total:</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesPayableCurrent_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionAxis__us-gaap--NonrelatedPartyMember_z8SrUI0azoi5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes payable">223,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

48500

175000

223500

48500

0.10

175000

26250

0.10

26250 28750

2025-03-12

NOTE 5. CONVERTIBLE NOTES PAYABLE On March 8, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 8% per annum. The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1") a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2") a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3") a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0.10% (one tenth of one percent)of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property As of December 31, 2023 $100,000 of the principal amount of the Note remains outstanding. On April 6, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 8% per annum. The maturity of the Note is three years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock, as such Common Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Common Stock shall hereafter be changed or reclassified pursuant to the following terms and conditions: (a) For the period beginning on the Issue Date and ending 365 days subsequent to the Issue Date (“Year 1") a 50% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or$150 per share (whichever is greater). (b) For the period beginning one day subsequent to the final day of Year One and ending 365 days subsequent to Year One (“Year 2") a 35% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater). (c) For the period beginning one day subsequent to the final day of Year 2 and ending 365 days subsequent to Year 2 (“Year 3") a 25% discount to the lowest Trading Price (as defined below) for the Common Stock during the ten (10) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the Conversion Date or $150 per share (whichever is greater). (d) “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by the Company and the Lender. “Trading Day” shall mean any day on which the Common Stock is tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Stock is then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by the Company relating to the Lender’s securities. The Company shall have the right, exercisable on not less than five (5) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. Upon closing of a Transaction Event the Lender shall receive 0.10% (one tenth of one percent) of the consideration actually received by the Company from an unaffiliated third party as a result of the closing of a Transaction Event. “Transaction Event” shall mean either of: (a) The sale by the Company of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property As of December 31, 2023 $50,000 of the principal amount of the Note remains outstanding. On October 31, 2016 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is two years from the issue date. The Lender shall have the right from time to time to convert all or a part of the outstanding and unpaid principal amount of this Note into fully paid and non- assessable shares of Common Stock and/or Series A Preferred Stock, as such Stock exists on the Issue Date, or any shares of capital stock or other securities of the Company into which such Stock shall hereafter be changed or reclassified at a conversion price of $18.75 per share. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. As of December 31, 2023 $50,000 of the principal amount of the Note remains outstanding. On May 5, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $200,000 for consideration consisting of $200,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is May 5, 2020. The Note is convertible into the Common Shares of Regen at a price per share (“Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $375 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iii) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $75 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company(“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31, 2023 $200,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $800,000 was recognized by the Company as of December 31, 2023. On December 20, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $100,000 for consideration consisting of $100,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is December 20, 2020. The Note may be converted into the Common Shares of Regen at a price per share (“Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $37.50 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $37.5 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31, 2023 $100,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $400,000 was recognized by the Company as of December 31, 2023. On October 3, 2017 (“Issue date”) the Company issued a Convertible Note (“Note”) in the face amount of $50,000 for consideration consisting of $50,000 cash. The Note pays simple interest in the amount of 10% per annum. The maturity of the Note is October 3, 2020. The Note may be converted into the Common Shares of Regen at a price per share (“Conversion Price”) equivalent to the lower of (a) a 75% discount to the closing price of the common stock of the Company on the trading day immediately prior to the date a conversion notice is given by the Lender to Regen or (b) $37.5 per common share as of the date which is the earlier of: (i) One day subsequent to the execution of an agreement to a transaction whose completion would result in a “Change of Control” of the Company or KCL Therapeutics. For purposes of this Note, a Change of Control shall be defined as any transaction or series of transactions, whether by merger, sale of substantially all of the assets, or sale or transfer of more than fifty percent (50%) of the outstanding stock of the relevant entity in which the members of the Board of Directors immediately preceding the closing of the Change of Control transaction no longer constitute a majority of the Board of Directors of the surviving entity following the closing of such transaction. (ii) One day subsequent to the commencement, in compliance with applicable law, of a broad solicitation by a third party to purchase a majority percentage of the Company’s outstanding equity securities for a limited period of time contingent on shareholders of the Company tendering a fixed number of their equity securities (“Tender Offer”). (iv) One day subsequent to a “Transaction Event”) Transaction Event” shall mean either of: (a) The sale by the Company or by KCL Therapeutics , Inc. of the Company’s proprietary NR2F6 intellectual property to an unaffiliated third party (b) The granting of a license by the Company or by KCL Therapeutics , Inc to an unaffiliated third party granting that unaffiliated third party the right to develop and/or commercialize the Company’s proprietary NR2F6 intellectual property (v) That date which is twenty four (24) months subsequent to the date of execution of this Note. The Company shall have the right, exercisable on not less than ten (10) Trading Days prior written notice to the Lender, to prepay the outstanding Note in part or in full, including outstanding principal and accrued interest. In the event that that the Company exercises its right to prepay the note, or if the Lender chooses not to convert the remaining amount of the note into Common Shares of the company, the Lender shall receive warrants equal to 10% of the Common shares it would have received had the Lender converted the remaining amount of the Note into Common shares of the Company. The warrants shall have a strike price of $37.5 per share. The warrants shall be exercisable: In the event that the Company exercises its right to Prepay the Note on or prior to the close of business on the three (3) month anniversary of the date that the Note shall have been prepaid by the Company (“Prepayment Date”) In the event , part of the outstanding and unpaid principal amount of this Note and any Accrued Interest remains outstanding on the Maturity Date of the Note, or prior to the close of business on the three (3) month anniversary of the Maturity Date of the Note As of December 31, 2023, $50,000 of the principal amount of the Note remains outstanding. The Company analyzed the conversion feature of the Note for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in the Company’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. The Company values the embedded derivative using the Black-Scholes pricing model and a derivative liability of $200,000 was recognized by the Company as of December 31, 2023. On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date. Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen. As of December 31, 2023, 10,000 of the principal amount of the Note remains outstanding. Zander and Regen are under common control. Zander Therapeutics, Inc. is the sole licensee of Regen’s NR2F6 intellectual property for veterinary applications.

100000

0.08

150

100000

50000

0.08

150

50000

0.10

18.75

50000

200000

0.10

200000

800000

100000

0.10

37.50

100000

400000

50000

0.10

37.5

50000

200000

350000

0.10

10000

NOTE 6. RELATED PARTY TRANSACTIONS On June 23, 2015 the Company entered into an agreement (“Agreement”) with Zander Therapeutics, Inc. (“Zander”) whereby The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by The Company (” License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander is under common control with the Company. Pursuant to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000) as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement. The abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander. Pursuant to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales , as such term is defined in the Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter. Pursuant to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Zander from sublicensees (excluding royalties from sublicensees based on Net Sales of any Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement). Zander is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($10,000) payable per year on each anniversary of the Effective Date of this Agreement, commencing on the second anniversary of June 23, 2015. This minimum annual royalty is only payable to the extent that royalty payments made during the preceding 12-month period do not exceed ten thousand US dollars ($10,000). The Agreement may be terminated by The Company: If Zander has not sold any Licensed Product by ten years of the effective date of the Agreement or Zander has not sold any Licensed Product for any twelve (12) month period after Zander’s first commercial sale of a Licensed Product. The Agreement may be terminated by Zander with regard to any of the License IP if by five years from the date of execution of the Agreement a patent has not been granted by the United States patent and Trademark Office to The Company with regard to that License IP. The Agreement may be terminated by Zander with regard to any of the License IP if a patent that has been granted by the United States patent and Trademark Office to The Company with regard to that License IP is terminated. The Agreement may be terminated by either party in the event of a material breach by the other party. On December 17, 2018 Regen Biopharma, Inc.(“Licensor”) , KCL Therapeutics, Inc. (“Assignee”) and Zander Therapeutics, Inc. (“Licensee”) entered into a LICENSE ASSIGNMENT AND CONSENT AGREEMENT whereby, with regards to certain intellectual property which was assigned by Regen Biopharma, Inc.(“Assigned Properties”) to its wholly owned subsidiary KCL Therapeutics, Inc., Licensor hereby transfers and assigns to Assignee all rights, duties, and obligations of Licensor under the Agreement with respect to the Assigned Properties , and Assignee agrees to assume such duties and obligations thereunder and be bound to the terms of the Agreement with respect thereto. On December 16, 2019 Zander Therapeutics, Inc. (“Zander”), KCL Therapeutics, Inc. (“KCL”) and Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) whereby: 1) Zander shall return for cancellation 194,285,714 shares of the Series A Preferred stock of Regen (“Conversion Shares”) acquired by Zander through conversion of $340,000 of principal indebtedness of a $350,000 convertible note payable issued by Regen to Zander. Subsequent to this event the principal amount due to Zander by Regen pursuant to the Convertible Note shall be $350,000 which shall be applied pursuant to the Agreement. 2) A $35,000 one time charge due to Zander by Regen (“One Time Charge”) shall be applied pursuant to the Agreement. 3) $75,900 of principal indebtedness due to Regen by Zander and $4,328 of accrued but unpaid interest due by Regen to Zander shall be applied pursuant to the Agreement. No actions were taken by any of the parties to enforce the terms of the Agreement. On April 15, 2021 the Agreement was amended as follows so that the material terms and conditions shall be: a) Zander shall not return the Conversion shares for cancellation and the principal indebtedness of the aforementioned convertible note shall not reflect such return b) As of December 16, 2019 all principal and accrued interest payable by Regen to Zander on that date resulting from Promissory Notes issued by Regen to Zander shall be credited towards amounts due by Zander pursuant to that agreement, as amended, entered into by and between Zander and Regen on June 23, 2015 (“License Agreement”) whereby Regen granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual property controlled by Regen for non-human veterinary therapeutic use for a term of fifteen years and that License Assignment And Consent agreement entered into by and between Regen, KCL and Zander on December 17, 2018 whereby Regen transferred and assigned to KCL all rights, duties, and obligations of Regen under the License Agreement and KCL agreed to assume such duties and obligations thereunder and be bound to the terms of the License Agreement with respect thereto. Zander and Regen are under common control. On September 30, 2018 Regen Biopharma, Inc. (“Regen”) issued a convertible promissory note in the principal amount of $350,000 (“Note”) to Zander Therapeutics, Inc. (“Zander”). Consideration for the Note consisted of $350,000. A onetime interest charge of 10% of the principal amount shall be applied to the principal amount of the Note. The Note is due and payable 24 months from the effective date. Zander has the right, at any time after the September 30, 2018, at its election, to convert all or part of the outstanding and unpaid Principal Sum and accrued interest (and any other fees) into shares of fully paid and non-assessable shares of Series A Preferred stock of Regen as per this conversion formula: Number of shares receivable upon conversion equals the dollar conversion amount divided by the Conversion Price. The Conversion Price is the greater of $0.0001 or 60% of the lowest trade price in the 25 trading days previous to the conversion. Zander, at any time prior to selling all of the shares from a conversion, may, for any reason, rescind any portion, in whole or in part, of that particular conversion attributable to the unsold shares and have the rescinded conversion amount returned to the Principal Sum with the rescinded conversion shares returned to Regen. As of December 31, 2023, $10,000 of the principal amount of the Note remains outstanding. On October 8,2021 the Company entered into an agreement with Dr. Brian Koos, MD PhD whereby Dr. Brian Koos would provide services to the Company consisting of : a) Reviewing existing publications on research being conducted on Checkpoint NR2F6. b) Identifying the most promising applications for the Company’s technology c) Drafting a “white paper” on results for 1(b) d) Making introductions to known experts in appropriate fields identified in 1(b). Dr. Brian Koos is to be paid compensated $117,000 as total consideration for performing the abovementioned tasks. During the quarter ended December 31, 2021 Dr. Brian Koos was paid the amount of $80,275 and during the quarter ended June 30, 2022 Dr. Brian Koos was paid $36,975. Dr. Brian Koos is the brother of David Koos the Chairman and Chief Executive Officer of the Company. As of December 31, 2023 the Company is indebted to David R. Koos the Company’s sole officer and director in the amount of $710. $<span id="xdx_905_eus-gaap--DebtInstrumentCarryingAmount_iI_pp0p0_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DavidKoosMember_zkW6L5nF41Hb" title="Due to related party carrying amount">710 lent to the Company by Koos is due and payable at the demand of the holder and bear simple interest at a rate of 15% per annum. On January 13, 2022 Regen Biopharma, Inc. entered into a sublease agreement with BST Partners (“BST”) whereby Regen Biopharma, Inc. would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from BST on a month to month basis for $5,000 per month beginning January 14, 2022. BST Partners is controlled by David Koos who serves as the sole officer and director of Regen Biopharma, Inc.

350000

10000

710

NOTE 7. STOCKHOLDERS’ EQUITY The stockholders’ equity section of the Company contains the following classes of capital stock as of December 31, 2023: Common stock, $ 0.0001 par value; 5,800,000 shares authorized: 3,750,565 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Common Stock shall receive, out of assets legally available for distribution to the Company’s stockholders, a ratable share in the assets of the Corporation. Preferred Stock, $0.0001 par value, 800,000,000 shares authorized of which 600,000 is designated as Series AA Preferred Stock: 34 shares issued and outstanding as of December 31, 2023, 739,000,000 is designated Series A Preferred Stock of which 409,551 shares are outstanding as of December 31, 2023, 60,000,000 is designated Series M Preferred Stock of which 29,338 shares are outstanding as of December 31, 2023, and 20,000 is designated Series NC stock of which 15,007 shares are outstanding as of December 31, 2023.. The abovementioned shares authorized pursuant to the Company’s certificate of incorporation may be issued from time to time without prior approval of the shareholders. The Board of Directors of the Company shall have the full authority permitted by law to establish one or more series and the number of shares constituting each such series and to fix by resolution full or limited, multiple or fractional, or no voting rights, and such designations, preferences, qualifications, restrictions, options, conversion rights and other special or relative rights of any series of the Stock that may be desired. Series AA Preferred Stock On September 15, 2014 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series AA Preferred Stock” (hereinafter referred to as “Series AA Preferred Stock”). The Board of Directors of the Company have authorized 600,000 shares of the Series AA Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times seven (7). Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series AA Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Series A Preferred Stock On January 15, 2015 the Company filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series A Preferred Stock” (hereinafter referred to as “Series A Preferred Stock”). The Board of Directors of the Company have authorized 739,000,000 shares of the Series A Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series A Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series A Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by the Corporation, and Series A Preferred Stock shall vote as a single class on all matters submitted to the stockholders. Holders of the Series A Preferred Stock will be entitled to receive, when, as and if declared by the board of directors of the Company (the “Board”) out of funds legally available therefore, non-cumulative cash dividends of $0.01 per quarter. In the event any dividends are declared or paid or any other distribution is made on or with respect to the Common Stock , the holders of Series A Preferred Stock as of the record date established by the Board for such dividend or distribution on the Common Stock shall be entitled to receive, as additional dividends (the “Additional Dividends”) an amount (whether in the form of cash, securities or other property) equal to the amount (and in the form) of the dividends or distribution that such holder would have received had each share of the Series A Preferred Stock been one share of the Common Stock, such Additional Dividends to be payable on the same payment date as the payment date for the Common Stock. Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary (collectively, a “Liquidation”), before any distribution or payment shall be made to any of the holders of Common Stock or any other series of preferred stock, the holders of Series A Preferred Stock shall be entitled to receive out of the assets of the Company, whether such assets are capital, surplus or earnings, an amount equal to $0.01 per share of Series A Preferred (the “Liquidation Amount”) plus all declared and unpaid dividends thereon, for each share of Series A Preferred held by them. If, upon any Liquidation, the assets of the Company shall be insufficient to pay the Liquidation Amount, together with declared and unpaid dividends thereon, in full to all holders of Series A Preferred, then the entire net assets of the Company shall be distributed among the holders of the Series A Preferred, ratably in proportion to the full amounts to which they would otherwise be respectively entitled and such distributions may be made in cash or in property taken at its fair value (as determined in good faith by the Board), or both, at the election of the Board. On January 10, 2017 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as “Series M Preferred Stock” (hereinafter referred to as “Series M Preferred Stock”). The Board of Directors of Regen have authorized 60,000,000 shares of the Series M Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series M Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series M Preferred Stock owned by such holder times one. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series M Preferred Stock shall vote as a single class on all matters submitted to the stockholders. The holders of Series M Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series M Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen. On March 26, 2021 Regen Biopharma, Inc. (“Regen”) filed a CERTIFICATE OF DESIGNATION (“Certificate of Designations”) with the Nevada Secretary of State setting forth the preferences rights and limitations of a newly authorized series of preferred stock designated and known as Nonconvertible Series NC Preferred Stock (hereinafter referred to as “Series NC Preferred Stock”). The Board of Directors of Regen have authorized 20,000 shares of the Series NC Preferred Stock, par value $0.0001. With respect to each matter submitted to a vote of stockholders of Regen, each holder of Series NC Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series NC Preferred Stock owned by such holder times 334. Except as otherwise required by law holders of Common Stock, other series of Preferred issued by Regen, and Series NC Preferred Stock shall vote as a single class on all matters submitted to the stockholders. The holders of Series NC Preferred Stock shall be entitled receive dividends, when, as and if declared by the Board of Directors in accordance with Nevada Law, in its discretion, from funds legally available therefore On any voluntary or involuntary liquidation, dissolution or winding up of Regen, the holders of the Series NC Preferred Stock shall receive, out of assets legally available for distribution to Regen’s stockholders, a ratable share in the assets of Regen.

0.0001

5800000

3750565

0.0001

800000000

600000

739000000

409551

60000000

29338

20000

15007

NOTE 8. INVESTMENT SECURITIES, RELATED PARTY On June 11, 2018 Regen Biopharma, Inc. was paid a property dividend consisting of 470,588 of the common shares of Zander Therapeutics, Inc. On November 29, 2018 the Company accepted <span id="xdx_909_ecustom--NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest_c20181128__20181129__us-gaap--StatementClassOfStockAxis__custom--SeriesMPreferredStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zipixiEmpboh" title="Shares issued in satisfaction of prepaid rent and accrued interest, shares">725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. in satisfaction of prepaid rent and accrued interest owed to the Company collectively amounting to $<span id="xdx_908_ecustom--SharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterestValue_pp0p0_c20181128__20181129__us-gaap--StatementClassOfStockAxis__custom--SeriesMPreferredStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zM9qt4VhUwWh" title="Shares issued in satisfaction of prepaid rent and accrued interest, value">13,124. On December31, 2023 the Company revalued 470,588 of the common shares of Zander Therapeutics, Inc. and <span id="xdx_900_ecustom--NumberOfSharesIssuedInSatisfactionOfPrepaidRentAndAccruedInterest_c20231001__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMPreferredStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zfrKbAg5x9Re" title="Shares issued in satisfaction of prepaid rent and accrued interest, shares">725,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. based on the following inputs: <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_zQX0ijQV5UFi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Schedule of related party investment securities </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Fair Value of Intellectual Property</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--FairValueOfIntellectualProperty_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Fair Value of Intellectual Property">300,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prepaid Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--PrepaidExpenseCurrent_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid Expenses">65,661</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Due from Employee</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--DueFromEmployeeRelatedParty_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zMCt1flWGPOc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Due from Employee">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ReceivablesNetCurrent_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Note Receivable">40000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Interest Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--AccruedInvestmentIncomeReceivable_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest Receivable">35,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Investment Securities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--Investments_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities">258,255</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ConvertibleNoteReceivable_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible Note Receivable">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounts Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AccountsPayableCurrent_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accounts Payable">30,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Notes Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--NotesPayable_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable">400,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses Related Parties</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--AccruedExpensesRelated_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Expenses Related Parties">162,011</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Notes Payable Related Party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--NotesPayableRelatedPartyClassifiedCurrent_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable Related Party">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrent_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Expenses">647,072</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Enterprise Value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--EnterpriseValue_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Enterprise Value">1,948,562</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less: Total Debt</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtCurrent_iNI_pp0p0_di_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zEXQ1zjlmqG3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Total Debt">(1,239,646</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Portion of Enterprise Value Attributable to Shareholders</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_ecustom--PortionOfEnterpriseValueAttributableToShareholders_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Portion of Enterprise Value Attributable to Shareholders">708,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair Value per Shares</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_ecustom--FairValuePerShares_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zKuqTqrWx776" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value per Shares">0.02</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> The abovementioned constitute the Company’s sole related party investment securities as of December 31, 2023. As of December 31, 2023: <table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_z86shvbSmxwh" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Schedule of comprehensive income</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td colspan="15" style="font: 10pt Times New Roman, Times, Serif">470,588 Common Shares of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Basis</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">Total Unrealized Gains</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_989_ecustom--InvestmentSecuritiesBasis_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zUCT0bEF3LVa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment securities, Basis">5,741</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_984_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zMCjk9Du5kR1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment securities, Fair value">6,496</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98F_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zGPhUFEAvNKf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment securities, Total unrealized gains">755</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_980_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zZcUB67u1cBh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment securities, Net unrealized gain or (loss) realized">(81,112)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td colspan="15" style="font: 10pt Times New Roman, Times, Serif">725,000 Series M Preferred of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center">Basis</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center">Total Unrealized Loss</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">$</td> <td id="xdx_98A_ecustom--InvestmentSecuritiesBasis_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zkKiylcsNDz5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Investment securities, Basis">13,124</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">$</td> <td id="xdx_98D_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zM41vnuSGoZj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Investment securities, Fair value">11,238</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">$</td> <td id="xdx_989_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zmKC1I47Yrvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Investment securities, Total unrealized gains">(1,866)</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">$</td> <td id="xdx_987_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pp0p0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zy0A6Wn1fwcc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Investment securities, Net unrealized gain or (loss) realized">(123,733)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> 470588 725000 13124 470588 725000

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfOtherNonoperatingIncomeByComponentTextBlock_zQX0ijQV5UFi" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Schedule of related party investment securities </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 70%; text-align: justify">Fair Value of Intellectual Property</td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--FairValueOfIntellectualProperty_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right" title="Fair Value of Intellectual Property">300,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Prepaid Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_eus-gaap--PrepaidExpenseCurrent_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Prepaid Expenses">65,661</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Due from Employee</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_ecustom--DueFromEmployeeRelatedParty_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zMCt1flWGPOc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Due from Employee">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--ReceivablesNetCurrent_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Note Receivable">40000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Interest Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--AccruedInvestmentIncomeReceivable_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Interest Receivable">35,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Investment Securities</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--Investments_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment Securities">258,255</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible Note Receivable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--ConvertibleNoteReceivable_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Convertible Note Receivable">10,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounts Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AccountsPayableCurrent_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accounts Payable">30,563</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Notes Payable</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--NotesPayable_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable">400,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses Related Parties</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_ecustom--AccruedExpensesRelated_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Expenses Related Parties">162,011</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Notes Payable Related Party</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_ecustom--NotesPayableRelatedPartyClassifiedCurrent_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Notes Payable Related Party">0</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accrued Expenses</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--AccruedLiabilitiesCurrent_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Accrued Expenses">647,072</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Enterprise Value</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98B_ecustom--EnterpriseValue_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Enterprise Value">1,948,562</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Less: Total Debt</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98C_eus-gaap--DebtCurrent_iNI_pp0p0_di_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zEXQ1zjlmqG3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Less: Total Debt">(1,239,646</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Portion of Enterprise Value Attributable to Shareholders</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_988_ecustom--PortionOfEnterpriseValueAttributableToShareholders_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_pp0p0" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Portion of Enterprise Value Attributable to Shareholders">708,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Fair Value per Shares</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_983_ecustom--FairValuePerShares_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zKuqTqrWx776" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Fair Value per Shares">0.02</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table>

300000

65661

40000

35000

258255

10000

30563

400000

162011 0

647072

1948562

1239646

708916 0.02

<table cellpadding="0" cellspacing="0" id="xdx_890_eus-gaap--ScheduleOfComprehensiveIncomeLossTableTextBlock_z86shvbSmxwh" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - INVESTMENT SECURITIES, RELATED PARTY (Details 1)"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%">Schedule of comprehensive income</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td colspan="15" style="font: 10pt Times New Roman, Times, Serif">470,588 Common Shares of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Basis</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif">Total Unrealized Gains</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_989_ecustom--InvestmentSecuritiesBasis_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zUCT0bEF3LVa" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment securities, Basis">5,741</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_984_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zMCjk9Du5kR1" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment securities, Fair value">6,496</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_98F_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zGPhUFEAvNKf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment securities, Total unrealized gains">755</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td id="xdx_980_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_c20231001__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zZcUB67u1cBh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Investment securities, Net unrealized gain or (loss) realized">(81,112)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td colspan="15" style="font: 10pt Times New Roman, Times, Serif">725,000 Series M Preferred of Zander Therapeutics, Inc.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="3" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center">Basis</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center">Fair Value</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center">Total Unrealized Loss</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 17%; text-align: center">Net Unrealized Gain or (Loss) realized during the quarter ended December 31, 2023</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">$</td> <td id="xdx_98A_ecustom--InvestmentSecuritiesBasis_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zkKiylcsNDz5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Investment securities, Basis">13,124</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">$</td> <td id="xdx_98D_eus-gaap--DebtSecuritiesTradingAndEquitySecuritiesFvNiCost_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zM41vnuSGoZj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Investment securities, Fair value">11,238</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">$</td> <td id="xdx_989_ecustom--AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeLossTax_iI_pp0p0_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zmKC1I47Yrvi" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Investment securities, Total unrealized gains">(1,866)</td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> </td> <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">$</td> <td id="xdx_987_eus-gaap--EquitySecuritiesFvNiUnrealizedGainLoss_pp0p0_c20231001__20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesMMember__dei--LegalEntityAxis__custom--ZanderTherapeuticsMember_zy0A6Wn1fwcc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right" title="Investment securities, Net unrealized gain or (loss) realized">(123,733)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> </table>

5741

6496

755

-81112

13124

11238

-1866

-123733

NOTE 9. STOCK TRANSACTIONS On October 13 2023 the Company issued 16,710 common shares for cash consideration of $22,726. On October 27 2023 the Company issued 35,785 common shares for cash consideration of $46,091. On November 10, 2023 the Company issued 31,732 common shares for cash consideration of $38,205. On November 27, 2023 the Company issued 33,989 common shares for cash consideration of $32,629. On December 11 2023 the Company issued 43,297 common shares for cash consideration of $38,101. On December 20, 2023 the Company issued 82,686 common shares for cash consideration of $34,543.

16710

22726

35785

46091

31732

38205

33989

32629

43297

38101

82686

34543

NOTE 10. SUBSEQUENT EVENTS On January 3, 2024 the Company issued 94,883 common shares for cash consideration of $39,638. On January 10, 2024 the Company issued 82,643 common shares for cash consideration of $39,638.

94883

39638

82643

39638

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
M,"1)W'MP[WT4K]]3\>:_9Z/?4$L#!!0 ( )UK,UB7BKL

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